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 Abstract  
 
 
     This project was focused on the characterization of  muscarinic receptor subtype 
expression in lacrimal and salivary glands of the rat. Immunohistochemical methods 
were used to reveal the presence of the M1, M3 and M5 receptors and the expression of 
these subtypes was further studied under experimentally induced inflammatory 
conditions. The expression of the above mentioned muscarinic receptor subtypes was 
also studied in human labial glands, both healthy and with autoimmune sialadenitis 
compatible with Sjögren‟s syndrome.  
     M1, M3 and M5 muscarinic receptors were found in the lacrimal and submandibular 
glands of the rat using immunoenzyme and immunofluorescent methods. The M5 
receptor in the lacrimal gland was also detected on intracellular, possibly nuclear 
localization. The tissue with induced inflammation didn‟t show any significant 
differences in the muscarinic receptor expression. The immunofluorescent labeling of 
the M1 receptor in human labial glands with Sjögren‟s syndrome showed slight down-
regulation of this subtype. The M3 receptor was up-regulated, as well as the M5 
receptor, which showed apparent up-regulation.  
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Abstrakt 
 
 
     Tento projekt byl zaměřený na charakterizaci exprese podtypů muskarinových 
receptorů v slzních a slinných žlázách potkana. K odhalení přítomnosti M1, M3 a M5 
receptorů byly využity imunohistochemické metody a exprese těchto podtypů byla dále 
studována při experimentálně navozeném zánětu. Exprese výše zmiňovaných podtypů 
muskarinových receptorů byla taktéž studována v lidských pyskových žlázách zdravých 
a postižených autoimunitní sialadenitídou kompatibilní se Sjögrenovým syndromem.  
     Muskarinové receptory M1, M3 a M5 byly nalezeny v slzních a podčelistních 
žlázách potkana s využitím imunoenzymové a imunofluorescenční metody. M5 receptor 
byl v slzní žláze detekován v nitrobuněčném, eventuálně jaderném umístění. Tkáň s 
navozeným zánětem nevykazovala žádné významné změny v expresi muskarinových 
receptorů. Imunofluorescenční značení M1 receptoru v lidských pyskových žlázách se 
Sjögrenovým syndromem naznačilo mírnou down-regulaci tohoto podtypu. M3 receptor 
byl up-regulovaný, společně s M5 receptorem, který vykazoval výraznou up-regulaci. 
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1 Introduction  
 
 
     The autonomic nervous system regulates various functions throughout the body. 
This includes secretory as well as contractile functions, e.g. glands in the 
gastrointestinal tract and smooth muscles in the circulatory system. These effects are 
generally very well described in the literature.  
     However, besides the classical effects of the autonomic nervous system, it 
participates in the cross-talk with the immune system and has recently been described to 
affect inflammation, proliferation and tumor development.   
     The impact of changes of the parasympathetic influence on lacrimal and salivary 
glands has been thoroughly studied in the chronic autoimmune inflammatory disease 
Sjögrens‟s syndrome, which is primarily manifested by xerostomia and xerophtalmia. 
These conditions may seriously affect the quality of life of the patient and may also lead 
to further complications. This syndrome and inflammation in general may lead to 
alteration of the muscarinic receptor subtype expression pattern. This was shown both in 
Sjögren‟s syndrome labial glands, as well as in the urinary bladder during cystitis 
conditions. These changes in muscarinic receptor expression have been shown to be of 
functional significance in state of inflammation.  
     The expression of muscarinic receptors is well studied in salivary glands under 
normal conditions. However, in the lacrimal gland, there are only few reports, which 
leave space for further elucidation.  
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2 Review of literature 
 
2.1 The autonomic nervous system 
   
     The autonomic nervous system regulates various functions all over the body on the 
unconscious level and its main aim is to ensure self-preservation by maintaining 
homeostasis in the continuously changing environment. The ANS provides innervation 
to all organs of the body, except for the skeletal muscle, which is supplied by the 
somatomotor nervous system. The main functions regulated include the heart frequency, 
contraction and relaxation of smooth muscle, all exocrine and certain endocrine 
secretions and energy metabolism such as glucose utilization (especially in liver and 
skeletal muscle). (Rang 2003) 
     We can distinguish two major divisions of the ANS: the sympathetic and the 
parasympathetic nervous systems. Additionally, the ANS includes the enteric nervous 
system within the gastrointestinal tract. (Barrett and Ganong 2010) The latter one is 
capable of functioning independently of the central nervous system, in contrast to the 
sympathetic and parasympathetic divisions. In the classical view, the sympathetic and 
parasympathetic systems were apprehended as mere antagonists, but this has been 
shown to be true only in some situations, such as the control of heart rate or the 
gastrointestinal smooth muscle, while in e.g. salivary glands, they have complementing 
functions. (Rang 2003) 
     The main difference between the autonomic and somatic efferent pathways is that 
the autonomic pathway consists of two neurons, preganglionic and postganglionic, 
arranged in series, while the somatic pathway consists of a single motoneuron 
connecting the CNS to the skeletal muscle fibre. This means that all the actual efferent 
neurons lie outside the CNS, grouped to form ganglia. The preganglionic fibres passing 
from CNS to the ganglia are slow-conducting class B and C and release acetylcholine 
from their nerve terminals. The postganglionic fibres running from the ganglia to the 
tissues are slow-conducting, unmyelinated class C fibres and they travel together with 
fibres from the visceral sensory receptors forming the visceral nerves. (Petersen 2007) 
     Until the late 1970s, chemical transmission from autonomic nerves to their 
peripheral effector tissues generally had been thought to be mediated exclusively by 
norepinephrine or acetylcholine. However, even before the transmitter concept was 
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established, Heidenhain noticed that the muscarinic antagonist atropine did not 
eliminate all the functional responses to parasympathetic nerve stimulation of salivary 
glands. Later on, Johansson and Lundberg showed that acetlylcholine and vasoactive 
intestinal peptide (VIP) are co-localized in certain nerve endings in the submandibular 
salivary gland and lacrimal gland. (Johansson and Lundberg 1981) Another very 
significant observation was that acetylcholine caused relaxation of rabbit artery in the 
presence, but not in the absence of endothelium, thus cholinergic relaxation was shown 
as completely dependent on an endothelium-derived relaxing factor, which was in due 
course identified as nitric oxide. (Furchgott 1993) A subsequent body of evidence led to 
the general acknowledgement of the non-adrenergic, non-cholinergic transmission 
within the ANS. These transmitters include peptides, e.g. neuropeptide Y, substance P 
and VIP, the gas nitric oxide (NO) and adenosine-5‟-triphosphate (ATP). (Lundberg 
1996) 
 
2.1.1 The sympathetic nervous system 
 
     The sympathetic division of the ANS is sometimes also referred to as the 
thoracolumbar portion, because the preganglionic cell bodies are situated in the thoracic 
and upper lumbar segments of the spinal cord (T1-L3). Their myelinated fibres exit the 
spinal cord via the anterior spinal roots and then travel through the white rami 
communicantes to the paravertebral chain of sympathetic ganglia situated bilatteraly 
next to the spinal cord. The cell bodies of the postganglionic neurons are located here 
and their axons rejoin the spinal nerves through the grey rami communicantes for 
distribution to sweat glands and pilomotor muscles and to blood vessels of skeletal 
muscle and skin. However, the sympathetic fibres that innervate abdominal and pelvic 
viscera don‟t travel through the spinal nerves; they leave the paravertebral ganglia in 
visceral nerves instead. The postganglionic cell bodies are to be found in the unpaired 
prevertebral ganglia in the abdominen and the pelvis. The third type of sympathetic 
ganglia are the terminal ganglia located near the organs that they innervate; they include 
the ganglia connected to the urinary bladder and rectum and the cervical ganglia in the 
region of the neck. (Goodman, Hardman et al. 2001)      
     An interesting exception of the two-neuronal configuration is the innervation of the 
adrenal medulla, where the preganglionic sympathetic fibres don‟t synapse in the 
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ganglia, but travel directly to their destination, where they release acetylcholine. The 
cells of the adrenal medulla can thus be considered as modified postganglionic 
sympathetic neuronal cells, releasing epinephrine and norepinephrine into the blood 
stream. (Petersen 2007) 
     The sympathetic nervous system uses acetylcholine and norepinephrine as 
transmitters. Acetylcholine is released by preganglionic fibres of both sympathetic and 
parasympathetic fibres, and acts on nicotinic receptors. Norepinephrine, which acts on 
either α or β receptors, is released by all the postganglionic fibres, with the exception of 
the sweat glands, where transmission is mediated by acetylcholine acting on muscarinic 
receptors. However, cotransmission is a general phenomenon in the ANS and non-
adrenergic, non-cholinergic transmitters also play a significant role in the autonomic 
transmission. The main NANC transmitters of the sympathetic system are ATP and 
neureptide Y. (Rang 2003) 
     Activation of the sympathetic nervous system is primarily aimed at coping with 
stress, known as the “fight or flight” response. During rage and fright, all the 
sympathetically innervated structures of the body are affected simultaneously. This 
results in increased heart rate and contractility, pupillary dilatation, bronchodilatation, 
inhibition of gastrointestinal motility, constriction of the splanchnic vessels, elevation of 
glycaemia and free fatty acids, etc. Many of these effects are primarily casued by the 
release of epinephrine from the adrenal medulla. In addition, signals are conveyed to 
higher brain centers to facilitate meaningful responses or to imprint the event in 
memory. However, most of the activity of the sympathetic system is linked to 
homeostatic activity and it exerts localized actions, while its activity varies from organ 
to organ. (Goodman, Hardman et al. 2001) A more detailed description of the effects of 
sympathetic activation is given in Table 1.  
 
2.1.2 The parasympathetic nervous system 
 
     The preganglionic cell bodies of the craniosacral division of the ANS are situated in 
the sacral spinal cord (S2-4), the midbrain and the brainstem; the fibres from the brain 
are included in the III. (oculomotor), VII. (facial), IX. (glossopharyngeal) and X. 
(vagus) cranial nerves. The ganglia lie very close to the affected organs, resulting in the 
fact that the postganglionic nerves are very short in comparison with the sympathetic. 
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The neurons from the sacral portion travel to the pelvic ganglia, which carry both 
sympathetic and parasympathetic fibres.  
     The major transmitter of the parasympathetic nervous system is acetylcholine, 
released by preganglionic, as well as postganglionic neurons. Acetylcholine acts on 
nicotinic and muscarinic receptors. NANC transmission also plays an important role, 
mainly via VIP and nitric oxide. (Rang 2003) 
     The parasympathetic division is primarily aimed towards maintenance and 
conservation of bodily function. The main responses upon stimulation are decreased 
heart rate, contraction of the urinary bladder, constriction of the pupils and the ciliary 
muscle and increased motility and secretion in the gastrointestinal tract. (Petersen 2007) 
 
2.1.3 The enteric nervous system 
 
     The third portion of the ANS is very different from the previous two, as it forms a 
broad network where many cells are not affected by the CNS. The whole network of 
ganglia and their connecting axons is situated in the wall of the intestines, creating 
plexuses. The myenteric (Auerbach's) plexus is involved in control of digestive tract 
motility, while the submucosal (Meissner's) plexus regulates gastrointestinal blood flow 
and epithelial cell function. (Barrett and Ganong 2010) The enteric system contains 
numerous neurons transformed into mechano- and chemoreceptors which sense the 
environment of the intestinal lumen and can provide local reflex pathways without 
external input. The enteric nervous system is pharmacologically very complex and it 
involves various transmitters, such as neuropeptides, serotonin, NO and ATP, as well as 
acetylcholine and norepinephrine. (Rang 2003) 
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Table 1. The major effects of the autonomic nervous system 
 
Organ Sympathetic 
effect 
Adrenergic 
receptor 
type 
Parasympathe-
tic effect 
Main 
cholinergic 
receptor type 
Heart     
Sinoatrial node ↑ rate β1 ↓ rate M2 
Atrial muscle ↑ force β1 ↓ force M2 
Atrioventricular 
node 
↑ automaticity β1 
 
↓ conduction 
velocity 
Atrioventricular 
block 
M2 
Ventricular 
muscle 
↑ automaticity 
↑ force 
β1 No effect M2 
Blood vessels     
Arterioles 
   coronary 
 
constriction 
 
α 
  
   muscle dilatation Β2 No effect  
   viscera constriction α No effect  
   skin constriction α No effect  
   brain constriction α No effect  
   erectile  
   tissue 
constriction α Dilatation 
 
? M3 
   salivary   
   gland 
constriction α Dilatation ? M3 
Veins Constriction 
Dilatation 
α 
β2 
No effect 
No effect 
 
Viscera     
Bronchi 
   smooth  
   muscle 
 
 
No sympathetic 
innervation, but 
dilated by 
circulated 
  
β2 
  
Constriction 
 
M3 
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adrenaline 
Glands No effect  Secretion M3 
Gastrointestinal 
tract 
   Smooth 
    muscle 
   Sphincters 
   Glands 
  
 
 
↓ motility 
 
Constriction 
No effect 
 
 
 
α1, α2, β2 
 
α2, β2 
 
 
↑ motility 
 
Dilatation 
Secretion 
Gastric acid 
secretion 
 
 
M3 
 
M3 
M3 
M1 
Uterus 
   pregnant 
   non-pregnant 
 
Contraction 
Relaxation 
 
α 
β2 
 
Variable 
 
Lacrimal glands ?  Secretion M3 
 
Salivary glands Secretion α, β 
 
Secretion M3 
M1 
Eye 
Pupil  
Ciliary muscle 
 
Dilatation 
Relaxation 
(slight) 
 
α 
β 
 
 
Constriction 
Contraction  
 
M3 
M3 
 
Kidney Renin secretion β2 No effect  
Skin 
Sweat glands 
 
 
Pilomotor 
 
Secretion 
(mainly 
cholinergic) 
Piloerection  
 
α 
 
 
α 
 
No effect 
 
 
No effect 
 
Liver Glycogenolysis 
Gluconeogenesis 
α, β2 
 
No effect  
Male sex organs Ejaculation  α Erection ? M3 
 
Adapted from: Rang, H. P. (2003). Pharmacology. Edinburgh; New York, Churchill 
Livingstone. 
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2.2  Muscarinic acetylcholine receptors  
 
     Muscarinic receptors are responsible for the responses to parasympathetic 
stimulation mediated by the release of acetylcholine by parasympathetic postganglionic 
nerve fibres on the effector cells. Currently, five distinct muscarinic receptor subtypes 
are known, the M1, M2, M3, M4 and M5 receptors. They regulate numerous basic 
physiological functions and may have different roles within the same body system, with 
potential interplay between the subtypes, and they also play various roles in both central 
and autonomic nervous systems.  
     Their primary location in the peripheral nervous system is on autonomic effector 
cells innervated by postganglionic parasympathetic fibres. They can also be found in the 
ganglia and tissues with little or no cholinergic innervation, for instance on the 
endothelial cells of blood vessels (Tracey and Peach 1992) and are also present in high 
density in some structures of the central nervous system, where they are involved in 
various functions, such as motor control, temperature regulation, cardiovascular 
regulation and memory (Caulfield and Birdsall 1998). They are structurally much 
different from the other acetylcholine-activated receptors located in the autonomic 
ganglia and neuromuscular junctions, the nicotinic receptors. The nicotinic receptors 
consist of five protein subunits and are coupled to an ion-channel, while the muscarinic 
receptors are composed of only one protein, which has the same general structural 
features common to all members of the superfamily of seven transmembrane-helix G-
protein coupled receptors. (Felder 1995) 
     The classical approach to receptor classification is based on pharmacological 
agonists and antagonists. At first, two subtypes, the M1 and M2 receptors were 
distinguished on the basis of selective affinity to pirenzepine. (Hammer, Berrie et al. 
1980) Later on, four distinct muscarinic receptor genes lacking introns in the coding 
sequence subtypes were identified through the method of molecular cloning by  Bonner 
(1987) and this was followed by the cloning of the gene for the fifth muscarinic 
acetylcholine receptor. (Bonner, Buckley et al. 1987; Bonner, Young et al. 1988) The 
gene sequences show significant homologies with the other members of the G-protein-
coupled receptor superfamily (Hulme, Birdsall et al. 1990) and there is also a high level 
of similarity among different mammalian species.  
     Structurally, the muscarinic receptors consist of seven hydrophobic transmembrane 
helices linked together by three intracellular and three extracellular loops. The 
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intracellular third loop is critically involved in the process of determination of coupling 
selectivity and triggering different G-protein activation of M1/M3/M5 and M2/M4 
subtypes. (Wess, Liu et al. 1997) The receptor protein has an intracellular carboxy 
terminus and and extracellular amino terminus. 
 
 
Fig. 1. Schematic drawing of structure of the nicotinic and muscarinic receptor 
Adapted from: Felder, C. C., F. P. Bymaster, et al. (2000). "Therapeutic opportunities 
for muscarinic receptors in the central nervous system." J Med Chem 43(23): 4333-53. 
 
 
2.2.1 G-protein signalling  
 
     G proteins form a family of evolutionarily conserved, plasma membrane-associated 
signal transducers composed of an α subunit, which binds the guanine nucleotides GDP 
or GTP, and a tightly associated βγ heterodimer subunit. In mammals there are 20 α, 5 
β, and 11 γ chains that combine to form many distinct G-protein subtypes. The α 
subunits, which are used to name the G protein, are divided by structure into four main 
subfamilies (αi/o, αq, αs, and α12/13). (Paul 2003) They contain two domains: a 
GTPase
 
domain that is involved in the binding and hydrolysis of GTP
 
and a helical 
domain that buries the GTP within the core of
 
the protein. The helical domain is the 
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most divergent
 
domain among G  families and may play a role in directing specificity
 
of receptor- and effector- G protein coupling. (Cabrera-Vera, Vanhauwe et al. 2003) 
     Bacterial exotoxins have been proved as valuable tools in the identification of G 
proteins. Cholera toxin activates Gs by catalyzing ADP-ribosylation of specific amino-
acid residues in the α subunit, and therefore disables the hydrolysis of its bound GTP. 
Pertussis toxin blocks the receptor-mediated activation of Gi and Go, also by ADP-
ribosylation of the α subunit, resulting in the complex remaining bound to GDP. 
(Petersen 2007) 
     In the classic G-protein activation cycle, the binding of an agonist converts the 
receptor into a GEF (guanine nucleotide exchange factor), which catalyzes the exchange 
of GDP for GTP on the α subunit. This causes the G protein to leave the receptor, to 
dissociate into α and βγ subunits, which remain tethered to the plasma membrane by 
covalently attached lipid anchors on the α and γ chains, and to activate downstream 
intracellular effectors. The α subunit possesses slow intrinsic GTPase activity, and 
therefore acts as a timer. The intrinsic GTPase activity can be accelerated by one or 
more RGS proteins (regulators of G-protein signaling), these are the GTPase activating 
proteins for heterotrimeric G proteins. The result of this net is restoration of the GDP-
bound form of the α subunit, which then reassociates with βγ subunits and returns to 
new unoccupied receptors, thus completing the cycle. (Paul 2003)  
 
2.2.2 Muscarinic receptor subtypes      
 
     Muscarinic M1, M3 and M5 receptors are sometimes also called excitatory 
receptors, and are located mostly postsynaptically. They couple to pertussis toxin-
insensitive Gq/11, which is responsible for the activation of phospholipase C (PLC) that 
breaks down a minor membrane phospholipid, phosphatidylinositol bisphosphate (PIP2) 
into 1,4,5-inositol triphosphate (1,4,5-IP3) and diacylglycerol (DAG). 1,4,5-IP3 binds to 
and activates its receptors located in intracellular Ca
2+ 
stores, e.g. the endoplasmatic 
reticulum. This interaction results in the release of Ca
2+ 
into the cytosol. Activation of 
M1, M3, and M5 receptors can also trigger the activation of phospholipase A2, leading to 
the release of arachidonic acid and consecutive eicosanoid synthesis. (Felder 1995) 
     M2 and M4 receptors are presynaptic and preferentially couple to pertussis-toxin 
sensitive Gαi/o, which inhibits the activity of the enzyme adenylate cyclase and thereby 
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lowers the level of cAMP. In M2 signalling, the βγ subunit also directly activates the 
inward rectifier K
+
 channels in the heart. (Wickman and Clapham 1995) 
     Most cells, tissues and organs express multiple muscarinic acetylcholine receptor 
subtypes and while in some tissues one subtype may predominate in mediating a 
particular functional response, in others they may be of equal significance. 
     The M1 receptors are widely distributed in several structures of the brain, such as the 
hippocampus, neocortex and neostriatum. They are tightly connected to the processes of 
memory and learning, so agonists for this subtype have been proposed as potential 
treament for dementia or decrease of cognitive functions associated with Alzheimer‟s 
disease, aging or schizophrenia. They are expressed in some parts of the eye (Gil, 
Krauss et al. 1997), namely in the iris, sclera and lens epithelial cells, but their role 
hasn‟t been completely elucidated yet. This subtype plays a role in salivation, as 
discussed further, and is significant mainly for the the control of high-viscosity 
lubrication. In the nerve terminals of the urinary bladder, the prejunctionally located M1 
receptors facilitate transmitter release. (Chess-Williams 2002) In non-neuronal 
cholinergic functions, the M1 receptor has a role in immune response, as M1- knockout 
mice suffered from a defect in cytolytic T lymphocyte differentiation. (Zimring, Kapp et 
al. 2005) A role for the M1, along with M2 and M3 subtype, has also been proposed in 
tumor angiogenesis. (de la Torre, Davel et al. 2005) 
     The M2 receptor is abundant both in central and peripheral nervous systems. (Oki, 
Takagi et al. 2005) Selective M2 antagonists increase cholinergic overflow, as they 
reduce autoreceptor inhibitory function in both brain and the periphery, so they can be 
approached in the therapy of Alzheimer‟s disease. (Eglen 2006) The M2 subtype has a 
prominent function in the heart, where it modulates pacemaker activity, atrioventricular 
conduction and force of contraction. (Dhein, van Koppen et al. 2001) The bradycardia-
inducing effect was proved also by experiments on M2 knockout mice, where M2-
agonist- induced bradycardia was eliminated. (Stengel, Gomeza et al. 2000) In the 
brain, M2 receptors are expressed in the caudate putamen, where they act as inihibitory 
heteroreceptors on dopaminergic terminals (Eglen 2006), and they were also suggested 
to take part in cognitive processes (Tzavara, Bymaster et al. 2003). In the detrusor 
muscle of the urinary bladder, the M2 receptors  are even more densely expressed than 
the M3 receptors, even though their function is not completely clear. Experiments on 
knockout mice suggest that they may take part in the indirect mediation of bladder 
contractions by enhancing the contractile response to M3 receptor activation, and that 
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they may also mediate minor contractions to a certain extent. (Ehlert, Griffin et al. 
2005) The M2 receptors also predominate in the smooth muscles of lung, stomach, 
ileum and colon. (Levey 1993) In the lung, they are involved in the parasympathetic 
bronchial control and it seems according to experiments on murine airways that 
constriction is mediated by accordant activation of M2 and M3 receptors. (Struckmann, 
Schwering et al. 2003) In the gastrointestinal tract, they again outnumber the M3 
receptors (Gomez, Martos et al. 1992), but here they contribute to the contractility more 
than in the bladder. (Matsui, Motomura et al. 2000) 
     M3 receptors are also to be found in the central nervous system, but to lesser extent 
than the other subtypes. (Felder, Bymaster et al. 2000) Their central roles have not been 
completely elucidated yet, but the results of Yamada suggest that they may be involved 
in regulation of food intake. (Yamada, Miyakawa et al. 2001) This subtype mediates 
contraction of many types of smooth muscle in the respiratory, gastrointestinal and 
genitourinary organ systems. It plays a significant role in stimulation of gastrointestinal 
motility. (Matsui, Motomura et al. 2002) In the bladder, it predominantly mediates 
contraction of the detrusor muscle. The M3 receptors are also present in exocrine 
glands, namely the lacrimal and salivary glands, where they are the main subtype 
responsible for secretion. The M3 subtype is dominant also in the structures of the eye 
and it predominantly mediates ciliary muscle contraction, resulting in the classic effect 
of cholinergic agonists, miosis. (Poyer, Gabelt et al. 1994) In non-neuronal cholinergic 
function, the M3 receptor has been shown to play a role in vascular relaxation via NO 
release (Eglen and Whiting 1990), tumour growth and proliferation (Song, Sekhon et al. 
2003), inhibition of cell migration (Chernyavsky, Arredondo et al. 2004) and inhibition 
of apoptosis (Budd, Spragg et al. 2004).  
     In the central nervous system, the M4 receptors are co-localized with the 
dopaminergic receptors on projecting neurons of the corpus striatum. (Felder, Bymaster 
et al. 2000) The M4 subtype, together with the M2 receptors, account for the muscarinic 
anti-nociceptive effects both in spinal and supraspinal sites. (Duttaroy, Gomeza et al. 
2002) They are located prejunctionally on cholinergic nerve terminals of the urinary 
bladder, along with the M2, and inhibit the release of transmitters. (Chess-Williams 
2002)  
     The M5 subtype is abundant in several structures of the brain, including the ventral 
tegmental area, which provides major dopaminergic innervation to some limbic areas, 
and the compact part of substantia nigra, where it is the only muscarinic subtype present 
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in this structure providing the main dopaminergic innervation to the striatum. (Vilaro, 
Palacios et al. 1990) It seems to facilitate striatal dopamine release along with other 
muscarinic subtypes, including the M4. (Eglen and Nahorski 2000) The M5 receptor 
has been shown also in various non-neuronal tissues, e.g. fibroblasts and keratinocytes, 
lymphocytes, endothelial cells and smooth muscle of the neurovasculature. (Buchli, 
Ndoye et al. 1999) It is also present in the salivary glands (Ryberg, Warfvinge et al. 
2008) and in the eye on the iris sphincter (Gil, Krauss et al. 1997). The M5 receptor has 
so far been difficult to study because of the lack of selective M5 agonists; in particular it 
is very hard to distinguish between M3 and M5 mediated responses. Also no tissues in 
which the M5 receptor was the dominant muscarinic receptor subtype have been 
identified. (Ito, Oyunzul et al. 2009)  
  
 
2.3 Salivary glands 
 
     Saliva plays an important role in many physiological functions, such as lubrication 
of the oral mucosa, aid for swallowing and speech, promotion of remineralization of the 
teeth, and protection against microbial infections due to the bactericidal effect of 
lysozyme. Although saliva plays a minor role in digestion, it helps prepare the food 
bolus for swallowing and is a solvent for the tasteants which delivers them to taste buds. 
Saliva is hypotonic compared to the plasma and it is also alkaline, which is important 
for the neutralization of any eventual acid reflux. 
     Saliva is produced by the three pairs of major salivary glands and numerous minor 
glands (e.g. labial, palatal and buccal), which are located throughout the upper 
aerodigestive tract, mainly in the oral cavity and the oropharynx. The major salivary 
glands are the parotid, submandibular and the sublingual glands.  
 
2.3.1 Anatomy and histology of the salivary glands  
 
     The parotid glands are the largest salivary glands and they are located anteroinferior 
to the ear, overlying the mandibular ramus and masseter muscle. They extend medially 
between the mandibular ramus and the temporal bone to occupy the parapharyngeal 
space. The substance of the glands is divided into superficial and deep lobes by the 
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facial nerve. (Lalwani 2008) The drainage of the secretion of both glands is provided by 
a parotid duct, which empties into the vestibule.  
     The sublingual salivary glands are covered by the mucous membrane of the anterior 
floor of the oral cavity. A number of sublingual ducts open along both sides of the 
lingual frenulum. (Martini, McKinley et al. 2000) 
     The submandibular glands are located in the submandibular triangle together with 
lymph nodes and branches of the facial vein and facial artery. The hypoglossal, lingual 
and marginal mandibular nerves are all closely connected with the submandibular 
gland. 
 
 
 
Fig. 2. Anatomy of the salivary glands 
1 – Sublingual gland, 2 – Parotid gland, 3 – Submandibular gland 
Adapted from: Gray’s anatomy,   http://www.bartleby.com/107/242.html#i1024 
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     Histologically, the salivary glands are built up of lobules divided by septa of 
connective tissue. Each lobule is covered by a connective tissue capsule and consists of 
the acini, intercalated ducts, and small striated ducts. Larger striated ducts and excretory 
ducts are situated inside the connective tissue septa. The saliva produced by the 
secretory cells of the glands is carried through the tree-like network of these fine ducts 
which assemble into a central draining duct. This duct then penetrates the capsule and 
ends on the surface of the oral mucosa.  
     The acinus forms the distal part of the salivary unit. It consists of pyramidal 
secretory cells and myoepithelial cells intercalated between the basal sides of the 
secretory cells and the basement membrane. Acinar cells may be serous, mucinous, or 
seromucinous, which explains the different chemical compositions of the saliva of each 
gland. (Lalwani 2008) The parotid gland, for example, is dominated by serous secretory 
cells and produces thick secrete which contains a lot of enzymes, namely amylase, the 
first enzyme in the process of complex carbohydrates breakdown. The sublingual gland 
is dominated by mucous secretory cells and produces saliva rich in mucins. The 
submandibular gland contains both cell types and produces both type of saliva. The 
minor salivary glands mostly consist of seromucinous cells. The saliva in the mouth is a 
mixture of glandular secretions; about 70 % of the saliva originates in the 
submandibular glands, 25 % from the parotid gland and 5 % from the sublingual gland. 
All together, the salivary glands produce 1.0 – 1.5 litres of saliva a day, with the 
composition of 99.4 % water and various ions, metabolites, buffers and enzymes. 
(Martini, McKinley et al. 2000) 
 
2.3.2 Physiology and regulation of secretion of the salivary 
glands 
 
     The primary isotonic fluid of the saliva is produced in the acinary cells, which are 
water-permeable, in contrast to the ductal cells. As the forming saliva travels through 
the ducts, most Na
+
 and Cl
-
 are reabsorbed and a small amount of K
+
 and HCO
3-
 are 
secreted. Since the duct epithelium has low hydraulic conductivity, the reabsorbed ions 
are not followed by water and this results in hypotonic secretion. The final composition 
of the serous secretion varies with the rate of the flow; the higher the rate, the closer the 
ionic composition is to that of primary secretion. Increases in the flow of saliva may be 
caused by the stimulation of receptors in the mouth, pharynx and oesophagus.   
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Fig. 3. The salivary gland unit 
Adapted from:  Lalwani, A. K. (2008). Current diagnosis & treatment in 
otolaryngology- Head & neck surgery. New York, McGraw-Hill Medical. 
     Salivation is a reflex action and is completely under neural control. Afferent sensory 
fibres conduct information to salivary centres in the pons and medulla of the brain and 
efferent autonomic fibres innervate the glands. The salivatory centres also proceed 
impulses from higher brain centers. The salivatory response is a good example of the 
parasympathetic and sympathetic systems not acting as mere antagonists. Instead, here 
they have a similar, but not identical effect. Parasympathetic stimulation, being the most 
important, causes a prolonged abundant secretion relatively poor in protein and 
vasodilatation, which is due to the release of VIP, a co-transmitter in numerous 
parasympathetic postganglionic nerves. Nitric oxide also contributes significantly to 
vasodilatation. An indirect effect of the M1 receptor on arterial smooth muscle 
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relaxation was proposed via influencing the synthesis of NO. (Ryberg, Selberg et al. 
2008) Sympathetic stimulation produces a small quantity of thick mucous saliva, which 
is accompanied by vasoconstriction. (Petersen 2007) However, blood flow is not an 
initial limiting factor for secretion, because the interstitional fluid preserves the 
response for some time, until the intravascular oncotic pressure rises so much that the 
salivation lessens, unless the blood flow is increased. (Lung 1998; Thakor, Brown et al. 
2003)      
     The acetylcholine-mediated increase in the salivary secretion was originally imputed 
just to the muscarinic M3 receptor, but later binding and molecular experiments 
indicated the expression and functional role of muscarinic M1 receptor, and sometimes 
also the M5 receptor. It has been shown that in order to reach maximal glandular 
response, both M1 and M3 muscarinic receptors need to be activated concordantly. The 
M1 receptor seems to be of particular significance at low intensity of stimulation. 
(Tobin, Ryberg et al. 2006) Thus, the M3 receptors predominantly mediate salivatory 
response and are included in the control of saliva volume and secretions of both high 
and low viscosity, whereas the M1 receptor is included in the control of high-viscosity 
lubrication. (Abrams, Andersson et al. 2006) Muscarinic M4 and M5 receptors also 
seem to contribute to the secretion, based on mice knockout experiments, where the 
buccal cavity of M3-knockout mice remained lubricated. (Takeuchi, Fulton et al. 2002; 
Bymaster, McKinzie et al. 2003)  
     On the molecular level, the M3 receptor mediates the salivatory signal of 
acetylcholine binding by activating a pathway that results in the production of 1,4,5-IP3, 
which binds to and opens the 1,4,5-IP3 receptor on the endoplasmatic reticulum, leading 
to the release of Ca
2+
. This stimulates the Ca
2+
-induced release of Ca
2+
 via the 1,4,5-IP3 
receptor and the ryanodine receptor (activated by cyclic ADP ribose). Increased 
intracellular
 
Ca
2+
 activates the Cl
-
 channel embedded in the apical membrane, and the 
basolateral K
+
 channel. Efflux of Cl
-
 to the lumen od the acinar cell draws Na
+
 across 
the cell in order to maintain electrochemical neutrality, resulting in the osmotic 
gradient- generated fluid secretion. (Tobin, Giglio et al. 2009)  
     Prejunctional muscarinic receptors may alter parasympathetic signal transmission. 
Muscarinic M1 receptors usually facilitate the release of transmitter when the nerve 
activity is intense and short. (Tobin 1998) However, M2 and perhaps M4 receptors 
inhibit acetylcholine and peptide-mediated transmissions at low frequencies, but only 
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after some delay. (Tobin, Ryberg et al. 2006) Moreover, it was observed that a 
phenomenon of prominent enhancement of vasodilatation and secretion when compared 
with continuous stimulation occurs when the parasympathetic innervation is stimulated 
in burst pattern at high frequencies. This has been ascribed to the neuropeptides, which 
are preferetially released at high frequencies (Andersson, Bloom et al. 1982), and to the 
finding that short-lasting stimulation activates prejunctional facilitator and not 
inhibitory mechanisms. (Tobin 1998) 
     As for the tissue localization of the muscarinic receptor subtypes, according to the 
findings of Ryberg based on immunohistochemical staining on rat and ovine salivary 
glands, immunoreactivity for all of the muscarinic receptors was detected in the acini, 
except for the rat sublingual gland. A weaker occasional immunoreactivity for different 
muscarinic receptor subtypes was present in the ducts of different glands as well. M3 
receptors were expressed in the intraglandular vessels of rat submandibular and parotid 
glands. The M4 receptors were found on nerve fibres at the outer layer of the lobuli and 
the submandibular vessels also expressed M1 and M2 receptors, in contrast to the 
parotid gland. Occasionally, M5 receptors were apparent in the arteries and veins as 
well. (Ryberg, Warfvinge et al. 2008) 
     
2.4  Lacrimal gland  
 
2.4.1 Function of the tears 
 
     Tears form a complex thin film of fluids that continuously covers the exposed 
surfaces of the eye, the cornea and the conjunctiva. Tears have various functions which 
are crucial for preserving the health of the eye. They provide optimal pH, nutritients, 
proteins, electrolytes, lipids and mucin for the nourishment and enhancement of 
transparency of the avascular cornea. They protect the cornea and the conjunctiva from 
harmful environmental stresses, such as cold, bright light, decreased humidity, physical 
injury, mechanical stimulation, chemicals and bacterial, viral, or parasitic infections. 
The latter is achieved by proteins, namely lysozyme and lactoferin. The tight neural 
regulation allows the tear secretion to respond immediately to these changing 
conditions. Although there are multiple pathways to stimulate lacrimal gland secretion, 
defects can appear and decrease the amount or change the composition of the tears, thus 
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resulting in dry eye syndromes, which can seriously deteriorate the quality of life and 
even threaten normal vision. (Hodges and Dartt 2003) 
 
2.4.2 Anatomy and histology of the lacrimal gland 
 
     The main lacrimal gland is almond-shaped and is located within a depression in the 
frontal bone, at the roof of the orbit, superior and lateral to the eyeball. Anteriorly, it is 
divided into an upper (orbital) and lower (palpebral) lobe which is connected to the 
lateral superior conjunctival fornix by approximately 12 secretory ducts opening to the 
conjunctival sac (this applies to the human lacrimal gland, but the rat lacrimal gland is 
exorbital and secretes into a single long excretory duct). Structurally, it is similar to 
other exocrine ducts, as it consists of numerous small lobules made up of many fine 
branched tubules. These tubules consist of the actual secretory cells, the acinar cells, 
representing 80% of the mass of the gland. The tubules converge, forming interlobular 
ducts and then empty to the larger secretory ducts leading to the ocular surface. The 
secretory product is modified on its way through the ducts by the ductal cells.  
     The acinar cells are highly polarized due to the tight junctions surrounding the cells 
at the lumen and thus dividing the plasma membrane into apical (towards lumen) and 
basolateral (towards blood). This organization allows the secretion to flow in only one 
direction. The basolateral part contains receptors for the neurotransmitters and 
neuropeptides released from the proximate nerve endings, and transport proteins and 
ionic channels for the electrolyte- and water secretion. The cuboidal cells lining the 
ducts are also polarized and contain luminal tight junctions. Their main function is to 
secrete water and electrolytes, but they also secrete a limited amount of proteins. 
(Hodges and Dartt 2003)  
     The acinar and ductal cells are surrounded by the contractile myoepithelial cells, 
which  are stellate with numerous thin radial processes ended by freely terminated 
tapered endings. (Nagato, Yoshida et al. 1980) The functional role of these cells is 
probably to support the secretory processes by contraction of their multiple processes on 
the basal side.  They may also have structural role supporting the gland‟s shape. The 
lacrimal gland also contains a variety of components of the immune system, such as 
lymphocytes, plasma cells, mast cells and macrophages.  
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Fig. 4. The lacrimal apparatus. Gray‟s Anatomy of the Human body 
Adapted from: http://www.bartleby.com/107/illus896.html 
 
     The tear film consists of three layers, each of them are produced by different 
structures. The inner mucous layer is produced by the goblet cells of the conjunctiva 
and stratified squamous cells of the cornea and conjunctiva. This helps to prevent 
bacterial binding and also has a smoothing effect. The middle aqeous layer is secreted 
principally by the main lacrimal gland, and the much smaller accessory lacrimal glands 
of Krause and Wolfring situated in the stroma of the orbital conjunctiva. The outer lipid 
layer is a product of the Meibomian glands, which can be found at the rim of upper and 
lower eyelids. The main function of this layer is to prevent evaporation of the tears. The 
rate of tear production is about 1 ml/day.  
     Protein secretion of the lacrimal gland can be divided into regulated and constitutive. 
Regulated secretory proteins are stored in secretory granules, which fuse with the apical 
plasma membrane immediately after stimulation by classic neurotrasmitters, bioactive 
peptides or peptide hormones. Granules containing constitutive secretory proteins are 
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not stored, but fuse with the plasma membrane without need for stimulation. Steroid 
hormones control the rate of their synthesis. (Hodges and Dartt 2003) 
 
2.4.3 Innervation of the lacrimal gland  
 
    Lacrimal gland secretion is under hormonal and neural control.  The innervation is 
provided by the lacrimal nerve (sensory- afferent), the facial nerve (parasympathetic- 
efferent) and the sympathetic nerve fibres, which arise from the superior cervical 
ganglion. The lacrimal nerve carries sensory fibers from the lacrimal gland, and it is one 
of the three branches of the opthalmic division of the trigeminal nerve. (Tasman 2007) 
The parasympathetic fibres are the most densely distributed and contain acetylcholine 
and VIP. They surround the basolateral membranes of most of the acini. (Dartt, Baker et 
al. 1984) The sympathetic nerves which release norepinephrine as a mediator, end at 
some acini and blood vessels. They are present to a much less extent than 
parasympathetic fibres, though. Sensory nerves are much less dense than the autonomic 
nerves and contain calcitonine gene-related peptide (CGRP) and substance P. 
(Nikkinen, Lehtosalo et al. 1984) 
 
2.4.4 Receptors in the lacrimal gland 
 
     Secretion from the lacrimal gland is mainly stimulated by acetylcholine, acting on 
muscarinic receptors; VIP, acting on VIP1 and VIP2 receptors, and norepinephrine, 
stimulating α1 and β1 receptors. Muscarinic receptors are present on the basolateral 
membranes of acinar cells and the plasma membranes of myoepithelial cells, as it was 
shown by immunofluorescent labeling on the collagenase-digested acini preparations. 
(Lemullois, Rossignol et al. 1996) Hodges claims only the M3 receptor to be present in 
the lacrimal gland. (Hodges and Dartt 2003) However, the papers on which this 
statement is based are not completely convincing. Hootman conducted experiments on 
the avian salt glands (Hootman and Ernst 1981), and Mauduit characterized the 
muscarinic receptors only by pharmacological tools, using 4-diphenylacetoxy-N-
methylpiperidine (4-DAMP), which antagonizes the M1/M3/M5 receptors and therefore 
couldn‟t definitely distinguish between M3 and M5 receptors. In Northern blotting, no 
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probes for M4 or M5 receptors were used. Also no further molecular methods were 
carried out. (Mauduit, Jammes et al. 1993). This means that further investigation of the 
muscarinic network in the lacrimal glands should be carried out.  
     However, in contrary to other subtypes, the presence and the functional role of the 
M3 receptor is well established. The receptor interacts with a Gq/11 protein upon 
activation, which leads to production of 1,4,5-IP3 and DAG, as described before. 
Binding of 1,4,5-IP3 to its receptors on structures such as the endoplasmatic reticulum 
leads to the release of Ca
2+
 into the cytosol. This process seems to be biphasic and the 
immediate release of Ca
2+
 from intracellular stores is followed by a slower sustained 
phase caused by Ca
2+
 entry across the plasma membrane. (Bird, Rossier et al. 1991) The 
activation of Ca
2+ 
entry into the cell caused by Ca
2+ 
release
 
from the intracellular stores 
is called „the capacitative calcium entry“. (Berridge 1995) There are several theories to 
explain the mechanism. The first put up that the Ca
2+ 
decrease in intracellular stores 
triggered the release of a substance that activated the capacitative calcium channels of 
the membrane. (Randriamampita and Tsien 1993) However, this substance hasn‟t been 
identified yet. The second proposed a model of intracellular calcium stores-depletion 
regulated insertion of voltage-independent channels into the plasma membranes. 
(Fasolato, Hoth et al. 1993) This is referred to as the exocytosis model. The third theory 
involves conformational coupling between proteins on the intracellular stores and the 
capacitative Ca
2+
 entry channels. (Berridge 1995) The results of Sundermeier and Satoh 
obtained on single acinar cells indicate that the released Ca
2+
 from intracellular stores 
evoked fusion of secretory vesicles with the plasma membrane and leaded to exocytotis 
of secretory proteins. (Satoh, Sano et al. 1997; Sundermeier, Matthews et al. 2002) Ca
2+
 
entering through the capacitative channels is probably responsible for long-term protein 
secretion; this is supported by the results of chelation of the intracellular Ca
2+
, which led 
to inhibion of the initial rapid secretory phase, but was much less effective on prolonged 
secretion. (Hodges, Dicker et al. 1992) 
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Fig. 5. Schematic drawing of pathways activated by cholinergic agonists in the lacrimal 
gland to stimulate protein secretion.  
Adapted from Dartt, D. A. (2001). "Regulation of lacrimal gland secretion by 
neurotransmitters and the EGF family of growth factors." Exp Eye Res 73(6): 741-52. 
 
     DAG leads to activation of the enzyme family called protein kinase C, which 
includes 11 different isoforms, each of these having cell-and tissue-specific 
localizations and functions. These enzymes phosphorylate (and in this way activate) 
protein substrates on serine and threonine residues. They may play a role in cholinergic 
activation of lacrimal gland secretion. PKC –α  seems to induce protein secretion, while 
PKC -δ and –ε probably inhibit Ca2+ influx through the capacitative channels and 
thereby terminate secretion. (Hodges and Dartt 2003) 
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     Cholinergic agonists also lead to activation of phospoholipase D besides PLC. PLD 
hydrolyzes phosphatidylcholine and produces a free polar head group and phosphatidic 
acid, which may be degraded to generate DAG or may serve as a signalling molecule 
itself. However, the role of PLD in lacrimal gland secretion has not been determined 
yet. (Hodges and Dartt 2003) 
     However, it has been shown that acetylocholine doesn‟t exclusively stimulate 
secretion. Cholinergic agonists may also activate a pathway which actually supresses 
the secretory response. This is achieved through activation of mitogen-activated protein 
kinase (MAPK) pathway, by increased levels of intracellular Ca
2+
, activaton of PKC 
and subsequent activation of non-receptor tyrosine kinases. (Hodges, Rios et al. 2006) 
This finding was surprising, as activation of MAPK pathway is usually stimulatory. The 
purpose of this inhibitory pathway may be to regulate the amplitude of the secretory 
response. (Dartt 2009) 
 
2.4.5 Dry eye syndrome (keratoconjunctivitis sicca) 
 
     Generally speaking, dry eye syndrome is a tear film abnormality caused either by 
unsufficient tear production or altered composition of the tear fluid, leading to excessive 
tear evaporation. Thus, the syndrome can be divided into two major types: aqeous-
defficient dry eye caused by lacrimal gland diseases and evaporative dry eye caused 
mainly by diseases of the Meibomian glands. (Zoukhri 2006) Types of tear-deficient dry 
eye include Sjögren‟s syndrome, lacrimal disease, lacrimal obstructive disease, and 
reflex hyposecretion. Evaporative dry eye occurs even when the lacrimal function is 
normal and tear volume is sufficient. It can be caused by periocular disorders that 
interfere with tear film integrity, such as blepharitis, meibomian gland disease, and 
abnormalities with blinking. (McCabe and Narayanan 2009) 
     Under several pathological circumstances, the lacrimal gland can become a target of 
the immune system and get inflammed as a result of autoimmune diseases (such as 
Sjögren‟s syndrome), graft versus host disease after bone marrow transplantation, or as 
a result of aging. This leads to insufficient tear secretion and subsequently dry eye 
syndrome.  
     Millions of people all around the world suffer from the dry eye syndrome and mostly 
women and elderly people are affected. The patients mostly complain of scratchy or 
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sandy foreign body feeling, itching, excessive mucus secretion, inability to produce 
tears, a burning sensation, photosensitivity, redness, pain, and difficulty in moving the 
lids. Advanced forms of the syndrome may even lead to corneal ulceration, corneal 
thinning and perforation. Secondary bacterial infection may also occur, and corneal 
scarring and vascularization may result in significant impairment of vision. The 
treatment is usually restricted to alleviation of symptoms using artificial tear eye drops 
to replace the missing fluid.  
 
 
2.5  Inflammation 
 
2.5.1 Mechanisms of accute and chronic inflammatory response 
 
     Inflammation is a non-specific primary reaction of living tissue to injury, which can 
be due to many factors, such as mechanical, physical and biological. Symptoms and 
mechanism of inflammation should be considered after division into acute and chronic.  
     The acute inflammatory response lasts from minutes to few days and is characterized 
by the classic symptoms of rubor, calor, tumor and dolor, which have been recognized 
for thousands of years. Rubor and calor, or redness and heat, are caused by the 
increased blood flow and vascular permeability, leading to accumulation of protein-rich 
exudate and swelling (tumor). Dolor, pain is caused by stimulation of the nerve endings 
in the affected area by activated plasma kinins and histamine, which is being released 
from mast cells and basophils during the process. In response to injury, chemotaxins are 
being released from the damaged tissue, the microorganisms or as a product of 
complement-activation. This causes the leukocytes to migrate from the circulation into 
the affected area. The cells involved in the process of acute inflammation are 
neutrophils and macrophages, which are being transformed from monocytes when 
entering the tissue. The primary function of the macrophages is to phagocyte 
microorganisms and to remove remains of the damaged tissue. (Petersen 2007) 
Macrophages in addition produce TNF (tumour necrosis factor), which accounts for the 
main clinical symptoms of inflammation, and intensifies and prolongs the inflammatory 
response by activating other cells to release pro-inflammatory cytokins and mediators. 
(Tracey 2002) The immune system also produces antiviral interferons, derivatives of the 
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complement cascade and antibacterial and antitoxic antibodies, which may be found in 
the exsudate, thus contributing to inflammation. (Petersen 2007) 
     A widely used clinical marker for acute inflammation, C-reactive protein (CRP), 
plays several roles in the inflammatory process, including initiation of opsonization and 
phagocytosis and activation of complement, neutrophils, and monocytes. Its levels may 
increase significantly in 24 – 48 hours as high as 1000-folds. (McClatchey 2002)  
     The chronic inflammatory response is a highly regulated process that can last for 
weeks or months, sometimes even years. Mononuclear cells, such as lymphocytes, 
monocytes and plasma cells play the most important role. In contrast to acute 
inflammation, the chronic inflammatory response is characterized by proliferiation of 
capillaries and increased deposition of extracellular matrix components, which is 
essential for wound healing and repair. It can be triggered by persistent infection with a 
variety of microorganisms, long term exposure to insoluble exogenous particles, or by 
autoimmune diseases. The characteristics of the chronic inflammatory responses depend 
on the location and cause of the injury. The key cell type in the process are the 
macrophages that can be activated by -interferon secreted by antigen-activated T 
lymphocytes and microbial endotoxins, extracellular matrix proteins, or foreign 
particles. When activated, they enhance their phagocytal activity and secrete a wide 
variety of mediators, such as proteases, reactive oxygen and nitrogen intermediates, 
coagulation factors, arachidonic acid-derived lipids, cytokines, angiogenic factors (e.g. 
fibroblast growth factor), and profibrogenic growth factors (fibroblast growth factor, 
transforming growth factor- , platelet-derived growth factor). The lymphocytes, both T 
and B cells are also important. They are recruited by the same chemotactic mechanisms 
as neutrophils in acute inflammation, and also by leukocyte-endothelial adhesive 
interactions. Activated lymphocytes produce a wide range of proinflammatory 
mediators that are involved in immune regulation (e.g., IL-5 in IgE ) and in lymphocyte 
proliferation (e.g. IL-2). (Williams and Lichtman 2006) 
 
2.5.2 Regulation of the inflammatory process 
 
     The mechanisms that regulate the process of inflammation include mediators of both 
humoral and neural origin and their aim is to maintain the inflammatory response within 
physiological range. (Rosas-Ballina and Tracey 2009) Glucocorticoids, IL-10 and other 
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humoral anti-inflammatory mediators hold back the release or the effect of 
proinflammatory cytokines, while resolvins and lipoxins assist tissue healing. (Serhan 
and Savill 2005) Humoral mediators affect not only target cells but also other organs, in 
contrast to nerve-released mediators, such as norepinephrine and acetylcholine, which 
are targeted and act almost immediately. It was found out that the afferent portion of the 
vagus nerve, the major parasympathetic nerve, also transfers information about 
inflammatory processes in the periphery to the brain, while the efferent portion of the 
vagus nerve affects the inflammatory response. This mechanism is known as the 
inflammatory reflex. The efferent part of the inflammatory reflex, the cholinergic anti-
inflammatory pathway is composed of the efferent vagus nerve, acetylcholine and the 
α7 subunit of the nicotinic acetylcholine receptor. (Rosas-Ballina and Tracey 2009) 
     Borovikova has shown that acetylcholine significantly reduced the release of 
cytokines (TNF, IL-1 , IL-6 and IL-18), but not the anti-inflammatory cytokine IL-10, 
in lipopolysaccharide-treated human macrophage cultures. (Borovikova, Ivanova et al. 
2000) This indicates that acetylcholine only inhibits the production of pro-inflammatory 
cytokines. The α7 subunit of the nicotinic acetylcholine receptor plays a key role in the 
pathway, as it links the nervous and the immune systems. (Rosas-Ballina and Tracey 
2009) 
     However, a role for lymphatic muscarinic receptors has been proposed in the 
immune response as well. Muscarinic receptors have already been reported to mediate 
autocrine, non-neuronal functions of acetylcholine in various tissues. These functions 
are generally different from the roles of acetylcholine in neurotransmission and they 
include regulation of basic cell functions, such as differentiation, cell growth and 
apoptosis. (Eglen 2006) Lymphocytes have been shown to express various cholinergic 
components, including muscarinic receptors, where acetylcholine acts in autocrine 
manner. Lymphocytes have been shown to express all five subtypes of muscarinic 
receptors, both on mRNA and protein level. Activation of  M1, M3 or M5 receptors is 
probably involved in modulating immune responsiveness, because increases in 
intracellular Ca
2+
 were detected after agonist stimulation of T and B lymphocytes. 
(Kawashima and Fujii 2003). Later on, it was shown that the secretion of IL-6 was 
markedly reduced in immunized M1/M5 knockout mice, suggesting that these receptors 
modulate antibody class switching from IgM to IgG1 via cytokine production. However, 
there was no change was detected in the serum IgM level, so they probably don‟t take 
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part in the initial generation of the antibody response. (Fujii, Tashiro et al. 2007) 
Nomura suggested a connection between the activation of  M1 receptors and IL-2 
production and thus positive modulation of cell growth in human T lymphocytes 
(Nomura, Hosoi et al. 2003) and the M1 receptor has also been shown to play a role in 
the in the differentiation of CD8
+ 
into cytolitic T lymphocytes in in vitro experiments on 
mice (Zimring, Kapp et al. 2005). Fujii reported also that stimulation of either T- or B-
lymphocytes with their correspondent mitogen leads to up-regulation of M5 muscarinic 
receptor mRNA expression, suggesting that direct interaction between T-lymphocytes 
and B-lymphocytes or antigen presenting cells leads to up-regulation of cholinergic 
transmission in lymphocytes via M5 receptors. (Fujii, Watanabe et al. 2003) The exact 
physiological function of this receptor is not exactly known, but it has been shown to be 
coupled to nitric oxide synthase (Wang, Zhu et al. 1994) so it may be involved in the 
regulation of production of NO in lymphocytes. (Costa, Auger et al. 1995) 
     Muscarinic receptor subtypes were also reported to intermediate the inflammation-
influencing effect of acetylcholine within different organs. (Pavlov and Tracey 2006) 
The M3 subtype was characterized in the rat tracheal epithelium to mediate the release 
of prostaglandin E2 and activation of phospholipase A2. (Brunn, Wessler et al. 1995)  
Acetylcholine has also been reported to release lipoxygenase-derived neutrophil and 
monocyte chemotactic activity via the M1 receptor in the bronchial epithelium during 
airway inflammation. (Koyama, Rennard et al. 1992) M3 and M5 receptors were shown 
to stimulate differentiation of cultured inflammatory cells into monocytic/macrophagic 
cells. (Mita, Dobashi et al. 1996) This manifests the somewhat contradictory effects of 
muscarinic receptors on inflammation, as the central muscarinic receptors have an 
activating role in the regulation of the cholinergic anti-inflammatory pathway. (Pavlov, 
Ochani et al. 2006) Muscarinic receptors seem to take part in the remodelling processes 
occuring during chronic inflammatory diseases, asthma being an example. (Gosens, Bos 
et al. 2005) According to Budd, the M1, M3 and M5 muscarinic receptors may mediate 
protection against apoptotic cell death. (Budd, McDonald et al. 2003) The M2 receptor 
has been shown to trigger the production of the bioactive sphingolipid sphingosine-1-
phosphate (S1P). (Pfaff, Powaga et al. 2005) S1P stimulates proliferation of airway 
smooth muscle and release of cytokines, thus posesses inflammatory and proliferatory 
features. (Ammit, Hastie et al. 2001) However, the activation of muscarinic receptors on 
its own doesn‟t induce proliferation and cell growth; other co-acting pro-proliferatory 
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stimuli, such as epidermal growth factor (EGF) or platelet-derived growth factor 
(PDGF) are requiered to achieve this. (Krymskaya, Orsini et al. 2000; Gosens, 
Nelemans et al. 2003)  
                          
2.6 Sjögren’s syndrome  
 
     Sjögren‟s syndrome is named after the Swedish ophtalmologist Henrik Sjögren and 
it is a chronic inflammatory autoimmune and rheumatic disorder. It‟s primary form is 
characterized by lymphocytic infiltration of salivary and lacrimal glands, which leads to 
progressive xerostomia and xerophtalmia (so-called sicca complex) because of the lack 
of proper exocrine secretion of mucosal membranes. These invader cells are mostly 
CD
4+
 T-cells, which can produce IL-2, TNF α and other cytokines. (Fox and Kang 
1992) One third of the patients develops the secondary syndrome with systemic 
manifestations such as arthritis, fever and fatigue and in this state the disease involves 
other organs, such as kidneys, lungs, liver, blood vessels and lymph nodes. This results 
in extraglandular pronouncements, including small-vessel vasculitis, glomerulonephritis 
and peripheral neuropathy. (Tucci, Quatraro et al. 2005) The secondary syndrome can 
be associated with almost any of the autoimmune rheumatic diseases, mostly 
rheumatoid arthritis, systemic lupus erythematosus and systemic sclerosis. (Jonsson, 
Moen et al. 2002) Patients with major salivary involvement are at an increased risk of 
developing non-Hodgin lymphomas of the parotid and submandibular gland. A minority 
of patients also suffers from high-frequency hearing loss of cochlear origin. (Tucci, 
Quatraro et al. 2005)  
 
2.6.1 Prevalence and ethiology 
 
     Sjögren‟s syndrome occurs all around the world in all age categories and it‟s 
diagnosis must be confirmed by several blood, ophtalmologic and oral tests. Still, 
sometimes it takes years after the symptomes are onset to settle the final diagnose. Most 
of the patients are females between 40-50 years of age, with the female/male ratio 9:1, 
pointing to the role of sex steroid hormones. (Sullivan, Wickham et al. 1999) 
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     The etiology is multifactoral. Genetic predisposition may prominently contribute to 
the development of the disease and also family history of other autoimmune diseases is 
common for the patients. Different viruses have been presumed to play a role in the 
ethiology of the syndrome as well, because the salivary glands may be a site of latent 
infections. (Jonsson, Moen et al. 2002) These include the Eppstein-Barr virus (EBV), 
hepatitis C virus (HCV), human T-cell leukemia virus (HTLV)-1 and human 
immunodefficiency (HIV)-1. (James, Harley et al. 2001) In addition, a relationship 
between Sjögren‟s syndrome and Helicobacter pylori has been proposed, as both these 
conditions are under increased risk of mucosa-associated lymphoid tissue lymphoma 
development. (Isaacson and Spencer 1987)  
     A large number of various autoantibodies have been found in both primary and 
secondary Sjögren‟s syndrome, and their presence can in some cases be in relation to 
the extent and severity of the disease. (Jonsson, Moen et al. 2002) These antibodies are 
aimed against organ- and non-organ- specific antigens. (Zoukhri 2006) 
     The autonomic nervous system may play an important etiologic role in the 
pathogenesis of Sjögren‟s syndrome, as it mimics several symptoms of ANS failure. 
The major symptoms of the syndrome, xerophtalmia and xerostomia suggest cholinergic 
parasympathetic dysfunction, whereas frequently reported xeroses and decreased 
sweating is a result of sympathetic cholinergic failure. (Nikolov and Illei 2009) Another 
important symptome, fatigue, can also be contributed to ANS dysfunction. (Barendregt, 
Visser et al. 1998) It‟s known that the degree of innervation is not changed (Pedersen, 
Dissing et al. 2000), so the ANS abnormalities may be possibly mediated through 
interference with signalling via muscarinic receptors. (Nikolov and Illei 2009)  
 
2.6.2 Muscarinic receptors and Sjögren’s syndrome 
 
     The discovery of serum M3 receptor autoantibodies was a significant step towards 
understanding the pathogenesis of glandular function deterioration. These antibodies 
simulate the effect of muscarinic receptor agonists and eventually they lead to the loss 
of the secretory funtion as they prevent proper parasympathetic neurotransmission. 
(Bacman, Sterin-Borda et al. 1996) According to the findings of Beroukas, the M3 
muscarinic receptor expression is up-regulated in glandular acini in human labial 
glands. (Beroukas, Goodfellow et al. 2002) This was also confirmed by the results of 
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Ryberg, who reported up-regulation of M3, M4 and M5 receptors. (Ryberg, Warfvinge 
et al. 2008) The increased expression of M3 receptors is probably a result of long-term 
receptor blockade. (Tobin, Giglio et al. 2009) As for the M5 receptor, the up-regulation 
seems to be a common feature in inflammation. (Giglio, Ryberg et al. 2005) 
 
2.6.3 Salivary glands and Sjögren’s syndrome 
 
     The typical otolaryngological manifestations are xerostomia, which progressively 
makes swallowing and fluent speech difficult, burning oral sensation, frequent dental 
caries and chronic periodontitis. The mucosa of the oral cavity is dry, erythematosus 
and sticky. The lack of saliva can lead to atrophy of the tongue mucosa and mycotic 
infections. In addition, the progressive lymphatic infiltration of parotid glands is 
manifested by billateral swelling in half of the patients, and leads to ductal 
inflammation and acinar destruction. (Tucci, Quatraro et al. 2005) Another 
characteristic sign of Sjögren‟s syndrome in salivary glands is focal adenitis, which is 
found only in some of the labial salivary glands, and even there not in all the lobules. 
This is in contrast with the functional defect of the salivary glands. (Tornwall, 
Konttinen et al. 1997) 
     Loss of function of salivary glands is evaluated by measuring salivary flow rate 
(sialometry) and by chemical analysis of saliva (sialochemistry). According to Kalk, the 
saliva of the patients positive for Sjögren‟s syndrome had significantly changed 
composition in concentration of sodium, chloride, and phosphate and the flow rate of 
the submandibular and sublingual glands is fairly reduced, which may suggest their 
early involvement in the disease progression. (Kalk, Vissink et al. 2001) 
     For a long time it has been difficult to investigate the syndrome, due to the different 
criteria for the classification of the disease, and also partly because of the traditional 
approach to Sjögren‟s syndrome that the symptoms are a result of glandular tissue 
destruction. (Dawson, Smith et al. 2000) This interpretation of salivary glands 
pathophysiology was changed mainly by the findings that the glands of many patients 
comprise large amount of acinar tissue that is unfuctional in vivo (Humphreys-Beher, 
Brayer et al. 1999), but in vitro studies of  isolated acinar cells from patients showed 
them to be functional, although with lower sensitivity to acetylcholine stimulation. This 
indicates that the salivary secretion impairment must not be necessarily caused by 
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immune-mediated acinar cell destruction. (Dawson, Field et al. 2001) It has also been 
shown that the glandular responsiveness is not significantly changed with age, even if 
larger amount of acinar tissue is lost. (Heft and Baum 1984) In conclusion, glandular 
function may be due to abberant acinar function, which may be followed by atrophy in 
the end. The discovery of antimuscarinic autoantibodies could therefore unite the 
pathologies of glandular hypofunction in both primary and secondary Sjögren‟s 
syndrome (Dawson, Tobin et al. 2005), as it was shown that there were no significant 
differences between the salivary flows in each clinical variant. (Dawson, Holt et al. 
2001) The alternation of muscarinic receptor function by autoantibodies could also be 
responsible for extraglandular manifestations of Sjögren‟s syndrome, such as bladder 
irritability, among others. (Dawson, Tobin et al. 2005)  
     It was also proposed that the decreased secretory function may be caused by 
irresponsiveness of receptors, such as the α1-adrenergic, M1 and M3 muscarinic and 
NK-1 substance P receptors to activation. These are all coupled to protein-kinase C 
signalling pathway. The protein-kinase C family alters protein activity via 
serine/threonine phosphorylation. Their activation of PKC is essential for cell 
proliferation, differentiation, membrane transport, and gene expression. (Nishizuka 
1992) Single cells usually co-express different isoforms of PKC. Long-term activation 
of the PKC system may result in proteolytic degradation and depletion, following the 
initial activation. It was shown that some isoforms are defficient in acinar epithelial 
cells, which may also lead to defect signal transduction. (Tornwall, Konttinen et al. 
1997) These findings are in accordance with the presence of M3 autoantibodies, as they 
may lead to prolonged activation and depletion of some PKC isoforms.  
 
2.6.4 Lacrimal gland and Sjögren’s syndrome 
 
     The main ocular symptoms include dry eyes, characterized by burning, sandy and 
itchy sensations, redness of the conjunctiva and increased photosensitivity. 
     The lacrimal gland of patients with SS is vastly infiltrated by lymphocytes, but still 
they contain many healthy-looking acinar and ductal cells. However, the secretion of 
the tissue is significantly decreased, even if the remaining cell should produce enough 
tears to preserve the minimal tear layer, and this results in aqeous-defficient dry eye. 
This suggests that there may be an impairment in the neural innervation of the rest of 
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the healthy tissue. However, it was shown that there wasn‟t a noticeable change in the 
the density of parasympathetic innervation around the acini of Sjögren‟s syndrome 
model mice in the areas of normal acinar and ductal cells, demonstrating that the 
parasympathetic innervation is not changed with the progression of inflammation. This 
also applies for the sympathetic and sensory innervation. It was also found out that 
cellular response manifested by the increase in intracellular Ca
2+
 to exogenous stimuli is 
up-regulated, thus leading to denervation-like supersensitivity. (Zoukhri, Hodges et al. 
1998) The altered stimulation of secretion may therefore be caused by the disabled 
release of transmitters from nerve endings, proinflammatory cytokines like IL-1 β being 
one of these inhibitory factors. (Zoukhri, Hodges et al. 2002) IL-1 β may induce nitric 
oxide synthase iNOS in lacrimal gland epithelial cells and therefore increase NO 
production, which may play a role in lacrimal cell death. (Beauregard, Brandt et al. 
2003) 
 
2.6.5 Treatment of sicca complex in Sjögren’s syndrome patients 
 
     Currently, the treatment of most patients is restricted to alleviation of symptomes, 
including eye lubricants, saliva substitutes and pharmacological local and systemic 
stimulators of secretory functions. The main secretagogues are pilocarpine and 
cevimeline. Pilocarpine is a natural alcaloid, acts as a non-selective muscarinic agonist 
and was the first agent with demonstrable efficacy in this indication. (Mavragani and 
Moutsopoulos 2007) However, its usefulness is limited by its short action, necessitating 
frequent administration. Cevimeline is a quinuclidine derivative of acetylcholine that 
acts as a muscarinic agonist with higher affinity for the M3 receptor. Its half-life is 
longer than pilocarpine, so it can be administered three times daily and seems to 
improve the symptoms of dry mouth and the salivary flow rate significantly. (Weber 
and Keating 2008) Cevimeline has also been reported to be effective in improving dry 
eye symptomes in a clinical study, where it made a significant difference in subjective 
symptoms, tear dynamics and condition of the corneoconjunctival epithelium. (Ono, 
Takamura et al. 2004) 
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3 Aims 
 
     The aim of the present study is to investigate the presence of muscarinic receptor 
subtypes in the rat lacrimal and salivary glands, under normal and inflammatory 
circumstances. The questions concerned are: 
 
1) Is the M3 subtype the only one present in the lacrimal gland, and if not, which 
other subtypes are present? 
2) Are there any changes in expression of muscarinic receptor subtypes in healthy 
and inflammed lacrimal and salivary glands? 
3) Is our model of inducing inflammation with LPS effective enough to induce 
changes in muscarinic receptor expression? 
4) Are there any changes in expression of muscarinic receptor subtypes in healthy 
and focal adenitis human labial glands, which serve as a model for Sjögren‟s 
syndrome? 
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4 Materials and Methods 
 
4.1 Immunohistochemistry 
 
4.1.1 Introduction of the method 
 
     Immunohistochemistry (IHC) is the localization of antigens, e.g. proteins in tissue 
sections by the use of specific labeled antibodies through antigen-antibody interactions 
that are visualized by a marker such as enzyme or fluorescent dye. IHC is widely used 
in basic research to characterize the distribution and localization of biomarkers and 
differentially expressed proteins in distinct parts of a biological tissue. 
     Immunohistochemistry has apparent advantage over traditionally used enzyme 
staining techniques that identify only a limited number of proteins, enzymes and tissue 
structures, as it involves specific antigen-antibody reaction. Therefore, IHC has become 
a crucial technique and is widely used in many medical research laboratories as well as 
clinical diagnostics. 
     There are numerous IHC methods that may be used to localize antigens. The 
selection of a suitable method should be based on parameters such as the type of 
investigated specimen and the degree of required sensitivity. 
     Tissue preparation is one of the most important steps in the immunohistochemistry 
procedure. The fixation has to be adequate and prompt to ensure the preservation of 
tissue architecture and cell morphology. However, there is no universal fixative that is 
ideal for the demonstration of all antigens. In general, many antigens can be 
successfully demonstrated in formalin-fixed, paraffin-embedded tissue sections. The 
discovery and development of antigen retrieval techniques further enhanced the use of 
formalin as routine fixative for immunohistochemistry. The most common fixatives 
used for IHC are 4% paraformaldehyde in 0.1M phosphate buffer, 2% 
paraformaldehyde with 0.2% picric acid in 0.1M phosphate buffer and 4% 
paraformaldehyde, 0.2% periodate and 1.2% lysine in 0.1M phosphate buffer (PLP 
fixative). However, certain cell antigens do not survive routine fixation and paraffin 
embedding, so the use of frozen sections still remains essential for the demonstration of 
numerous antigens.  
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     The visualization of many antigens can be significantly improved by pretreatment 
with the antigen retrieval reagent that breaks the protein cross-links formed by formalin 
fixation and thereby uncovers hidden antigenic sites. The techniques involved the 
application of heat for varying lengths of time to formalin-fixed, paraffin-embedded 
tissue sections in an aqueous retrieval solution. So the retrieval of the epitopes may be 
induced by heat or alternatively by proteolytic enzyme digestion. Heat causes cross-
linked protein epitopes to unfold and the buffer solution helps in maintaining the 
conformation of the unfolded protein. Microwave oven, pressure cooker and steamer are 
the most commonly used heating devices. Citrate buffer of pH6.0 is the most popularly 
used retrieval solution and is suitable for most of antibody applications. The TRIS-
EDTA of pH9.0 and EDTA of pH8.0 are second most used retrieval solutions.  
     The next significant step of the IHC procedure is the blocking of non-specific 
background staining, as inadequate or delayed fixation or impure antigens used for 
immunization of the animal which produces the secondary antibody may give rise to 
false positive results. But usually the main cause of non-specific background staining is 
non-immunological binding of the specific immune sera by hydrophobic and 
electrostatic forces to certain sites within tissue sections. This form of background 
staining is usually uniform and can be reduced by blocking of those sites with normal 
serum. Endogenous peroxidase activity is found in many tissues and can also be the 
cause of non-specific staining leading to false-positive results. The solution for 
eliminating endogenous peroxidase activity is pretreatment of the tissue section with 
hydrogen peroxide before the incubation with primary antibody. 
     As every valid scientific method, IHC also requires controls in order to test the 
protocol and the specificity of the antibody being used. Positive control is to test a 
protocol or procedure and make sure it works. Usually tissues of known staining results 
are used. If the positive control tissue showed negative staining, the protocol or 
procedure needs to be checked until a good positive staining is obtained. Negative 
control is to test for the specificity of an antibody involved. No staining must be shown 
when omitting primary antibody or replacing the specific primary antibody with normal 
serum.  
     Two methods, direct and indirect are commonly used in IHC. Direct method is one 
step staining method, and involves a labeled antibody reacting directly with the antigen 
in tissue sections. This procedure is short and quick, but it‟s main disadvantage is 
insensitivity due to little signal amplification and therefore it is rarely used. The indirect 
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method involves an unlabeled primary antibody which reacts with tissue antigen, and a 
labeled secondary antibody reacting with primary antibody. It is very important that the 
secondary antibody must be against the IgG of the animal species in which the primary 
antibody has been raised. This method is more sensitive due to signal amplification 
through several secondary antibody reactions with different antigenic sites on the 
primary antibody. In the indirect immunofluorescent method, the secondary antibody is 
labeled by a fluorescent dye, while in the indirect immunoenzyme method, the 
secondary antibody is labeled by an enzyme, e.g. peroxidase. There are various versions 
of the indirect method, such as the PAP method (Peroxidase Anti-Peroxidase), LSAB 
method (Labeled StreptAvidin Biotin) or the ABC method (Avidin-Biotin Complex). 
 
 
 Fig. 6. Scheme of immunofluorescent labeling 
 
     The ABC method is a standard and widely used technique for immunohistochemical 
staining. Avidin, a large glycoprotein, can be labeled with peroxidase or fluorescein and 
has a very high affinity for biotin. Biotin, a low molecular weight vitamin, can be 
conjugated to a variety of biological molecules such as antibodies. The technique 
involves three layers. The first layer is unlabeled primary antibody. The second layer is 
biotinylated secondary antibody. The third layer is a complex of avidin-biotin 
peroxidase. The peroxidase is then developed by the DAB (3,3'-diaminobenzidine) or 
other substrate to produce different colorimetric end products. 
 
Adapted from: http://www.ihcworld.com/introduction.htm 
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Fig. 7.  Scheme of the ABC staining method 
     
4.1.2 Immunohistochemistry procedure 
 
     The rat submandibular, parotid and lacrimal glands were used in this experiment. 
Male rats of the Sprague-Dawley strain with weight of 250-300 g were used in the 
current thesis. The study was approved by to local ethical committee of Göteborg 
University. The tissues were dissected out from the animal after the it had been 
anaesthetized by intraperitoneal injection of medetomidin (Dormitor, Orion Pharma, 
Finland) at a dose of 0.1 mg/kg and then was killed by carbon dioxide. The specimens 
were fixed in phosphate buffered 4 % paraformaldehyde (pH 7.0), and then embedded 
in paraffin. For the immunohistochemical investigation of muscarinic receptor 
expression, sections of different specimens were prepared in a cryostat at a thickness of 
4 m. These steps were done by HistoCenter, Västra Frölunda, Göteborg.  
     On every glass, there are two slices of the tissue, the left one on the plus side is used 
as the tested section, and the right one is used as negative control. This setup ensures 
that the controls and the tested specimens are processed under the same circumstances. 
The procedure itself takes two subsequent days. The first step is the de-paraffinization 
by heating the slides to 60 °C for 60 minutes and by immersing them into 100% xylene. 
Then they are re-hydrated by serial incubations in decreasing concentrations of ethanol, 
followed by running deionised water and tris-buffered saline (TBS) solution, which is 
used almost after every step to wash out the previously used solutions and to inactivate 
the ongoing reactions. Then the sections are immersed in 0.1 M citrate buffer (pH 6.0) 
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and microwaved to rupture the membranes and break protein cross-links. Endogenous 
peroxidase activity is blocked by 0.3 % aqueous solution of hydrogen-peroxide. Non-
specific protein binding is then blocked with 5% goat serum in TBS (the goat serum 
was used instead of the usual bovine serum albumin, because we observed better 
staining results on the lacrimal gland, if the non-specific background is blocked by a 
serum of the animal in which the secondary antibody was produced). This is followed 
by the most important step of the day, the incubation with the primary antibody 
overnight at room temperature in a humidified chamber with polyclonal rabbit anti-
mAChR subtype-specific antibodies raised in rabbit diluted in a ratio 1:100 in TBS 
containing 1% goat serum.  
     On the second day of the immunoenzyme ABC method, the specimens are incubated 
with biotinylated secondary antibody raised in goat of the Santa Cruz ABC Kit. It is 
very important to use the kit that is directed against the species of the primary antibody, 
which means against rabbit in this case. The following steps are the incubation with the 
AB enzyme reagent and subsequently with Peroxidase substrate reagent. Finally, the 
slices are counterstained with Mayer‟s haematoxyline, which selectively stains the cell 
nuclei with blue colour, after neutralizing the acid form in warm tap water to produce 
the insoluble blue complex of the reagent. Now that the staining is completed, the slices 
are gradually rehydrated in baths with increasing concentrations of ethanol and 100% 
xylene, then fixed with Pertex glue and covered by a coverslip. 
     The second day procedure of the immunofluorescenct method is different from the 
immunoenzyme method. The sections are incubated with fluorescently marked 
antibody. All the steps have to be carried out in darkness or at least shadow. Afterwards, 
the specimens are dehydrated in increasing concentrations of ethanol. Xylene was 
skipped in this method. After drying, ProLong medium is applied to the sections to 
preserve the signal for longer time. The sections are finally analysed by the use of 
fluorescence microscope. 
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4.1.3 Materials for the immunohistochemistry 
Anti-muscarinic M1 and M5 receptor antibodies produced in rabbit (Research & 
Diagnostic Antibodies, USA); Anti-muscarinic M2 and M3 antibodies produced in 
rabbit (Sigma); Mayer‟s haematoxyline (HistoLab, Gothenburg, Sweden); Pertex 
(HistoLab, Gothenburg, Sweden); Goat serum (Sigma); AlexaFluor 488 goat anti-rabbit 
IgG (Invitrogen, USA); ProLong Gold antifade reagent (Invitrogen, USA); ABC 
staining system SC 2018 for use with rabbit primary antibodies containing blocking 
goat serum, biotinylated goat anti-rabbit IgG, avidin, biotinylated HRP, substrate buffer, 
peroxidase substrate and DAB chromogen (Santa Cruz Biotechnology, USA); Xylene 
(HistoLab, Gothenburg, Sweden); Ethanol 99.5%, 95%, 85%, 70% (Kemetyl, Sweden); 
Hydrogen peroxide (Sigma); Sodium citrate (Sigma), Citric acid (Sigma), Sodium 
chloride (Sigma), Trizma base (Sigma)  
 
Microscope:    Nikon Eclipse 90i 
Camera:   Nikon DS- Fi1  
Magnification:   Ocular: 10x Objective: 20x 
Software:    NIS-Elements D 3.10, Laboratory Imaging, Nikon 
All pictures shown together and being compared in the Results part were taken under 
the same settings.  
 
4.1.4 Inducement of inflammation in the salivary and lacrimal 
glands of rat by LPS  
     A male rat of the Sprague-Dawley strain with the weight of 260 g had been injected 
by a 10 µg/kg dose of buprenorfine (Temgesic, Schering-Plough) followed by an 
intraperitoenal injection of lipopolysaccharide at a dose of 100 µg/kg. LPS is a major 
component of the outer membrane of Gram-negative bacteria, acts as an endotoxin and 
elicits strong inflammatory responses in animals. The rat was kept in its cage with 
access to water and food ad libitum for 24 hours. After this the rat had been 
administered an intraperitoneal dose of medetomidin (Domitor, Orion Pharma, Finland) 
and was killed by carbon dioxide, the organs were dissected and kept in phosphate 
buffered 4 % paraformaldehyde. The organs showed macroscopical features of 
inflammation, such as swelling and redness. The tissue was sent for processing to the 
HistoCenter, Västra Frölunda, Göteborg.  
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5 Results 
5.1 Immunohistochemistry of the lacrimal gland 
 
 
 
Fig. 8. Immunohistochemical labeling of the M1 muscarinic receptors in the rat lacrimal gland by 
immunoenzyme method. The upper row shows healthy tissue, the row below shows LPS-treated tissue. 
The negative controls are on the left and the right side pictures show the staining for M1 receptors. All 
sections were counterstained with Mayer‟s haematoxyline.  
 
     Fig. 8. shows the results of immunohistochemical labeling of the M1 muscarinic 
receptors in the rat lacrimal gland. Positive results for the binding of the M1 antibodies 
on both pictures of the right column can be observed, manifested by brown staining. 
The pictures show the acini of the lacrimal gland, consisting of column-shaped serous 
cells organized in a circle. The acinar cells are polarized, which means that the nuclei 
and the receptors for the neurotransmitters are generally localised in the basolateral part, 
while the apical part is dominated by secretory granules. The acini are separated by thin 
layers of connective tissue. The myoepithelial cells cannot be distinguished in this view. 
The staining pattern shows specific brown staining on the basolateral sides of acinar the 
cells in both the healthy and LPS-treated tissue.  
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Fig. 9. Immunohistochemical labeling of the M3 muscarinic receptors in the rat lacrimal gland by 
immunoenzyme method. The upper row shows healthy tissue, the row below shows LPS-treated tissue. 
The negative controls are on the left side and the right side pictures show the staining for M3 receptors. 
All sections were counterstained with Mayer‟s haematoxyline.  
 
     Fig. 9. shows the results of immunohistochemical labeling of the M3 muscarinic 
receptors in the rat lacrimal gland. The same structures and staining pattern can be 
observed as in Fig.8., although the staining for the M3 receptor may seem a little bit 
weaker. The receptors are again localized in the right side pictures in the basolateral 
portions of the acinar cells. In these pictures any major differences between the normal 
and LPS-treated tissue cannot be observed.  
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Fig. 10. Immunohistochemical labeling of the M5 muscarinic receptors in the rat lacrimal gland by 
immunoenzyme method. The upper row shows healthy tissue, the row below shows LPS-treated tissue. 
The negative controls are on the left and the right side pictures show the staining for M5 receptors. All 
sections were counterstained with Mayer‟s haematoxyline.  
 
 
     Fig. 10. shows the results of immunohistochemical labeling of the M5 muscarinic 
receptors in the rat lacrimal gland. The pictures show positive staining for the M5 
receptor, which is manifested by specifically brown coloured areas around the 
basolateral membranes of the acinar cells when compared to the negative controls. The 
nuclei are also of darker colour than on the controls. The LPS-treated lacrimal tissue in 
the lower left corner shows similar localization and intensity of staining as the healthy 
tissue in the upper right corner. 
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Fig. 11. Immunohistochemical labeling of the M1 muscarinic receptors in the rat lacrimal gland by 
immunofluorescent method. The upper row shows healthy tissue, the row below shows LPS-treated 
tissue. The negative controls are on the left and the right side pictures show the labeling of M1 receptors.  
 
     Fig. 11. shows immunofluorescent labeling of the M1 muscarinic receptor in the rat 
lacrimal gland. The controls on the left side show almost no or very weak emission of 
light, the bright spots are just artefacts. However, the pictures on the right side, which 
were exposed to the primary anti-muscarinic M1 receptor antibody, show pronounced 
and specific emission of light, which can be observed as green colour. On the tissue we 
can see acini separated by thin layers of connective tissue, but the actual acinar cells 
cannot be distinguished. The pattern of binding of the primary antibody is similar to the 
pattern seen on the pictures stained by immunoenzyme method, and is situated on the 
basolateral membranes of the acinar cells. The LPS-treated tissue in the left lower 
corner shows a similar intensity of colour as the healthy tissue. 
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Fig. 12. Immunohistochemical labeling of the M3 muscarinic receptors in the rat lacrimal gland by 
immunofluorescent method. The upper row shows healthy tissue, the row below shows LPS-treated 
tissue. The negative controls are on the left and the right side pictures show the labeling of M3 receptors.  
 
Fig. 12. shows immunofluorescent labelling of the M3 muscarinic receptor in the rat 
lacrimal gland. The pictures on the right show slightly brighter green colour than the 
controls, and even though the emission is not very intensive, the presence of the 
receptors is clearly visible on the basolateral portions of the acinar cells. The intensity 
of the labeling is rather weak, in accordance with the intensity of staining for the M3 
receptor in the immunoenzyme method. The healthy and LPS-treated tissue shows 
similar intensity of light emission.  
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Fig. 13. Immunohistochemical labeling of the M5 muscarinic receptors in the rat lacrimal gland by 
immunofluorescent method. The upper row shows healthy tissue, the row below shows LPS-treated 
tissue. The negative controls are on the left and the right side pictures show the labeling of M5 receptors. 
 
Fig. 13. shows immunofluorescent labeling of the M5 muscarinic receptor in the rat 
lacrimal gland. On these pictures also several small ducts can be observed. The 
emission of light by the bound fluorescent antibody is very apparent in the tissues on the 
right side, which was incubated with the primary anti-muscarinic M5 antibody. The 
labelling is very obvious around the basolateral membranes of the acini and looks very 
much alike to the labeling pattern of the immunoenzyme method, including the bright 
spots resembling the nuclei. The bright green colour is apparent on both the acinar and 
the ductal cells. There is no significant difference between the colour intensity of the 
healthy and LPS-treated tissue.  
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5.2 Immunohistochemistry of the submandibular gland 
 
 
Fig. 14. Immunohistochemical labeling of the M1 muscarinic receptors in the rat submanidbular gland by 
immunoenzyme method. The upper row shows healthy tissue, the row below shows LPS-treated tissue. 
The negative controls are on the left and the right side pictures show the staining for M1 receptors. All 
sections were counterstained with Mayer‟s haematoxyline.  
 
 
     Fig. 14. shows immunohistochemical labeling of the M1 muscarinic receptors in the 
rat submandibular gland. Characteristic structures of the submandibular gland can be 
observed on the pictures, namely the acini composed of the smaller serous cells and the 
acini composed of larger mucous cells . The cells are again polarized in structure, the 
nuclei are situated closer to the basolateral membrane, which is especially visible in the 
mucous cells. Specific staining for the M1 receptor occurs in both the serous and 
mucous cells, in both the healthy and the LPS-treated specimens. However, the staining 
in the mucous cells seems to be more intense.  
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Fig. 15. Immunohistochemical labeling of the M3 muscarinic receptors in the rat submanidbular gland by 
immunoenzyme method. The upper row shows healthy tissue, the row below shows LPS-treated tissue. 
The negative controls are on the left and  the right side pictures show the staining for M3 receptors. All 
sections were counterstained with Mayer‟s haematoxyline.  
 
 
     Fig. 15. shows immunohistochemical labeling of the M3 muscarinic receptors in the 
rat submandibular gland. Both the healthy and the LPS-treated glandular tissue shows 
positive staining for M3 receptors, localized more pronouncedly in the mucous cells, 
but also in the serous cells. The colour intensity of the staining seems a little darker in 
the LPS-treated tissue. 
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Fig. 16. Immunohistochemical labeling of the M5 muscarinic receptors in the rat submanidbular gland by 
immunoenzyme method. The upper row shows healthy tissue, the row below shows LPS-treated tissue. 
The negative controls are on the left and the right side pictures show the staining for M5 receptors. All 
sections were counterstained with Mayer‟s haematoxyline.  
 
 
     Fig. 16. shows immunohistochemical labeling of the M5 muscarinic receptors in the 
rat submandibular gland. The pictures on the left side shows controls which underwent 
the same procedure as the sections shown on the right side, only the primary antibody 
was omitted. On the positive sections, both healthy and LPS-treated, specific staining 
can be again observed in the mucous and serous cells, more markedly in the acini 
consisting of mucous cells.  
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5.3 Immunofluorescent labeling of human accessory labial 
glands 
 
 
This experiment was conducted to reproduce the results from the previous report of 
Ryberg et al. (Ryberg, Warfvinge et al. 2008)  
 
     The ethical committee of human trials of the MAS University Hospital, Malmö, 
approved the examination procedures of the human tissue. This was obtained from 
routine biopsies for the assessment of Sjögren‟s syndrome. Some specimens were taken 
from histologically normal labial glands, while others were taken from patients with 
autoimmune sialadenitis compatible with Sjögren‟s syndrome. The glandular tissue was 
dissected out under local anesthesia and sent for ordinary pathological examination 
fixed in buffered 4% paraformaldehyde.  
 
 
Fig. 17. Immunohistochemical labeling of the M1 muscarinic receptors in human labial gland by 
immunofluorescent method. The upper row shows healthy tissue, the row below shows tissue from gland 
with autoimmune sialadenitis. The negative controls are on the left and the right side pictures show the 
labeling of M1 receptors.  
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     Fig. 17. shows immunofluorescent labeling of the M1 receptor in human healthy and 
sialadenitis labial glands. The labial glands consist of seromucinous acinar cells. The 
controls on the left side show almost no or very weak emission of light manifested by 
green colour. The pictures on the right side, which were exposed to the primary anti--
muscarinic M1 receptor antibody, show apparent labeling of the receptors on the acinar 
seromucinous cells, and also on ductal cells. The sialadenitis specimen in the left lower 
corner shows lower expression of M1 receptors.  
 
 
 
Fig. 18. Immunohistochemical labeling of the M3 muscarinic receptors in human labial gland by 
immunofluorescent method. The upper row shows healthy tissue, the row below shows tissue from gland 
with autoimmune sialadenitis. The negative controls are on the left and the right side pictures show the 
staining for M3 receptors.  
 
     Fig. 18. shows immunofluorescent labeling of the M3 receptor in human healthy and 
focal sialadenitis labial glands. Again we can observe labeling on acinar cells in the 
specimens incubated with the primary anti-muscarinic M3 antibody. The specimen from 
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patients with focal sialadenitis shows more pronounced labeling of the M3 muscarinic 
acetylcholine receptor. 
 
 
 
 
Fig. 19. Immunohistochemical labelling of the M5 muscarinic receptors in human labial gland by 
immunofluorescent method. The upper row shows healthy tissue, the row below shows tissue from gland 
with autoimmune sialadenitis. The negative controls are on the left and the right side pictures show the 
labeling of M5 receptors.  
 
     Fig. 19. shows immunofluorescent labeling of the muscarinic M5 receptor in human 
healthy and sialadenitis labial glands. The binding of the anti-muscarinic antibody is 
revealed by emission of light, which can be seen as green colour on the pictures. The 
expression of the M5 receptors in the healthy tissue is apparent mainly in and around 
the acini in a patchy pattern. The sialadenitis specimen shows significantly more 
pronounced labeling.  
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5.4 Summary of the immunohistochemistry results 
 
 
 
 
Table 2. Results summary of the immunohistochemistry of the lacrimal gland 
Receptor 
 
Healthy tissue 
- IE method 
Healthy tissue -  
IF method 
LPS-treated tissue 
- IE method 
LPS-treated tissue 
– IF method 
 
 
M1 
 
+ ++ + ++ 
M3 
 
+ (+) (+) (+) 
M5 
 
++ +++ ++ +++ 
Parenthesis indicate weak labeling and +++ indicates very pronounced. 
 
 
 
Table 3. Results summary of the immunohistochemistry of the submandibular gland 
Receptor 
 
Healthy tissue - IE method LPS-treated tissue - IE method 
 
M1 
 
+ + 
M3 
 
(+) + 
M5 
 
+ (+) 
Parenthesis indicate weak labeling and ++ indicates very pronounced. 
 
 
 
Table 4. Results summary of the immunohistochemistry of the human labial glands 
Receptor 
 
Healthy tissue - IF method Focal sialadenitis tissue - IF method 
 
M1 
 
++ (+) 
M3 
 
(+) ++ 
M5 
 
+ +++ 
Parenthesis indicate weak labeling and +++ indicates very pronounced. 
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6 Discussion  
 
 
     Muscarinic receptors are widely expressed all over the body‟s organ systems. The 
expression and functional significance of the muscarinic M1, M2 and M3 receptor 
subtypes has been thoroughly studied in most organs, while less is known about the M4 
and, in particular, the M5 receptor subtypes. Muscarinic receptors have been found to 
carry out numerous neuronal as well as non-neuronal cholinergic functional roles. 
(Eglen 2006) Lately it has been suggested that the muscarinic receptors subtypes are 
also connected to inflammation and proliferation. (Ventura, Pennefather et al. 2002) 
     In the lacrimal gland, however, not that many studies have been carried out and 
that‟s why one of the aims of this thesis was to investigate the muscarinic network 
further. Most reviews describe a homogenous population of M3 receptors (Hodges and 
Dartt 2003). However, the actual experiments on which these statements are based, are 
not completely excluding the presence of other subtypes. In pharmacological 
experiments of Mauduit et al., non-selective antagonists pirenzepine and 4-DAMP were 
used to determine the identity of the present muscarinic receptors. (Mauduit, Jammes et 
al. 1993) Pirenzepine is said to block mainly M1, then M4 and then M3 and M5 
muscarinic receptor. 4-DAMP is said to block M1, M3 and M5 and possibly M4 
muscarinic receptors. So none of these could distinguish between M3 and M5 receptors, 
as so far no selective M5 antagonist has been synthesized. In the paper by Mauduit et 
al., also Northern blotting was carried out, but no probes were used for M4 and M5 
receptors, and even the mRNA for M2 receptors in the heart could be detected only very 
weakly, although the presence of this subtype is generally well proved. This indicates 
possible problems with the sensitivity of the performed method. In the publication of 
Ubels et al., the M3 subtype is also stated as the only muscarinic receptor subtype 
present in the lacrimal gland based on cDNA microarray analysis using the whole rat 
embryo as a reference. (Ubels, Hoffman et al. 2006) In the paper of Nakamura et al., the 
M3 subtype was found to carry out cholinergic-mediated protein secretion, but again, 
only relatively selective antagonists were used, namely pirenzepine, gallamine and 4-
DAMP, so the presence and a functional role for the M5 receptor cannot be completely 
excluded. (Nakamura, Tada et al. 1997) 
     In this thesis project, the rat lacrimal gland was investigated for the presence of 
muscarinic receptors using the method of immunohistochemistry, both immunoenzyme 
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and immunofluorescent. Anti-muscarinic M1, M3 and M5 receptor antibodies were 
used. The presence of the receptors was revealed by the comparison of the brown 
staining intensity (in the immunoenzyme method) or by the green light emission 
intensity (in the immunofluorescent method) of the specimens incubated with primary 
anti-muscarinic receptor subtype antibody to the negative controls, where the primary 
antibody was omitted. The results suggest the presence of all three subtypes.  
     As seen on Fig. 8., in the specimens incubated with anti-M1 antibody, specific 
brown staining can be observed in the basolateral portion of the acinar cells, which is in 
agreement with the histological structure of the lacrimal acini, as the acinar cells are 
highly polarized and the receptors are generally localized in the basolateral part. In the 
immunofluorescent method, the results shown in Fig. 11., the labeling pattern is the 
same as in the immunoenzyme method and is clearly apparent. This suggests that the 
M1 receptor may be present in the lacrimal gland, and as previous functional studies 
haven‟t shown any significant role in the protein secretion, it may possibly participate in 
other functions.  
     The results from the slides incubated with the anti-M3 antibody (Fig. 9. and 12.) 
show a weaker signal according to both methods, but still the presence of the receptors 
is visible. The receptors are again localized on the basolateral side of the acinar cells. As 
the antibodies for different muscarinic receptor subtypes have different binding 
properties, it‟s not possible to compare the extent of the receptor expression of the 
different receptor subtypes. That‟s why even though the M3 subtype shows weaker 
signal than the others, only the presence of the receptor can be assumed. The possible 
explanation for the weaker signal, even though the presence of the M3 receptor is well-
proved, may be that the anti-M3 antibody has generally weaker binding potency than 
the antibodies for the other subtypes, as previously experienced in immunoblotting by 
this group (Ryberg, Warfvinge et al. 2008). Also even though the M3 receptor seems to 
be the most important for the secretory function of the lacrimal gland, it may not be the 
quantitatively most present.  
     The results for the M5 receptor are somewhat unexpected. The immunoenzyme 
method (Fig. 10.) showed intense brown staining in the basolateral portions of the 
acinar cells, suggesting the presence of the M5 receptor. The colour of the nuclei is also 
much darker then on the negative controls. The immunofluorescent method (Fig. 13.) 
showed a very pronounced signal in both acinar and ductal cells and moreover, in 
structures resembling the nuclei. In fact the labeling pattern is very similar to that of the 
 63 
immunoenzyme method, pointing to a possible presence of the M5 muscarinic receptor 
subtype on the nuclear membrane. This was previously reported by Lind et al. (1995), 
who used a covalently binding muscarinic acetylcholine receptor-specific ligand to 
examine the expression of muscarinic receptor subtypes in the rabbit corneal epithelial 
and endothelial cells and in subcellular fractions of these cell types. Their results 
suggest that mAChR ligand-binding structures may be present on the nuclear 
membranes of the corneal cells, and one of these structures resembled the M5 subtype. 
(Lind and Cavanagh 1995) This suggestion could be very well related to the reported 
role of the M5 receptor in cellular growth (Kohn, Alessandro et al. 1996) and the role of 
muscarinic receptors in proliferation (Klapproth, Reinheimer et al. 1997), as well as to 
the possible anti-apoptotic potency of the M5 receptor (Budd, McDonald et al. 2003). 
     Acetylcholine elicits its effects influencing inflammation within different organs 
mainly via the α7 subunit of the nicotinic acetylcholine receptors, but muscarinic 
receptors have been shown to participate in inflammatory processes as well. The M5 
receptor has been shown to be up-regulated in lymphocytes upon immunological 
stimulation (Fujii, Watanabe et al. 2003) and in the rat urinary bladder under cystitis 
conditions (Giglio, Ryberg et al. 2005). This leads to the next aim of the current thesis, 
to compare the muscarinic receptor expression in the healthy tissue and the tissue with 
experimentally induced inflammation. For this purpose injection of lipopolysacharide 
was used. The organs were removed after 24 hours and they showed apparent 
macroscopical signs of inflammation, such as swelling and redness.  
     In the lacrimal gland, no significant difference could be seen in the intensity of 
labeling of the M1, M3 and M5 receptors when comparing the labeled healthy tissue 
opposed to the control and the LPS-treated labeled tissue opposed to its own control. 
The LPS-treated tissue showed the same pattern of labeling for all the three muscarinic 
receptor subtypes, and the slightly different shade and organization of the cells on the 
healthy and LPS-treated tissue is probably due to slightly different angle of cutting 
while the tissue was processed. Similar results were obtained by both immunoenzyme 
and immunofluorescent method. No conclusions can be drawn about up- or down-
regulation of the M1, M3 and M5 receptors under these conditions. This suggests that 
either there is no change in the expression of these receptor subtypes, or the 
inflammation was not powerful enough to trigger these changes or, most likely, longer, 
up to chronic inflammatory conditions are required to change the expression of these 
muscarinic receptors.  
 64 
     In the submandibular gland, the muscarinic network has been previously well 
described and M1, M3 and M5 receptors were all shown to be present. (Ryberg, 
Warfvinge et al. 2008) The results of this thesis confirm these findings. Specific 
staining was achieved for the M1, M3 and M5 receptors in both the serous and mucous 
acinar cells, although the staining seemed to be more pronounced in the mucous cells. 
The labeling of the M3 receptors (Fig. 15.) showed again weaker signal, as experienced 
in the lacrimal gland. The intensity of the staining in healthy and LPS-treated tissue was 
very similar, and didn‟t allow for drawing any conclusion about up- or down-regulation. 
The reason for this has been already discussed. The slightly different shade of the 
staining and organization of the tissue is again probably caused by the different angle of 
cutting while processing the specimens. 
     The next aim of this thesis was to investigate if there were any changes in expression 
of muscarinic receptor subtypes in healthy and focal adenitis human labial glands, 
which served as a model for Sjögren‟s syndrome. These experiments were conducted to 
confirm the previous results of Ryberg et al. (Ryberg, Warfvinge et al. 2008) The results 
of this thesis are in complete agreement with the above mentioned publication.  
     The M1 receptors have been detected on the seromucinous acinar cells of the labial 
glands and on the ductal cells (Fig. 17.). The specimen with focal sialadenitis showed 
weaker labeling of the receptors, suggesting down-regulation of this subtype during the 
progression of Sjögren‟s syndrome. As the M1 receptor is involved in the control of 
high-viscosity salivary secretion (Abrams, Andersson et al. 2006) and maximal 
salivation can be reached by simultaneous activation of both M1 and M3 receptors 
(Culp, Luo et al. 1996), the down-regulation can be an additive factor leading to 
hyposalivation.  
     The M3 receptor was also present on acinar cells (Fig. 18.). The up-regulation of the 
M3 subtype expression in the focal sialadenitis specimen was apparent when compared 
to the healthy tissue, which is consistent with previous reports. (Beroukas, Goodfellow 
et al. 2002; Ryberg, Warfvinge et al. 2008) This may be explained by the presence of 
autoantibodies aimed at the M3 muscarinic receptor in Sjögren‟s syndrome patients. 
The up-regulation of the M3 receptors is probably the result of their long-term blockade 
by these autoantibodies.  
     The M5 receptors could be seen on the sections in and around the acini in a patch-
like pattern (Fig. 19), which may resemble the labeling pattern of the M5 receptor in the 
lacrimal gland (Fig. 13). However, the focal sialadenitis specimen showed much more 
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pronounced expression of the M5 receptor, pointing to the up-regulation of this subtype 
during Sjögren‟s syndrome. This phenomenon seems to be a common feature of chronic 
inflammation. The M5 receptor was reported to be coupled to activation of NO synthase 
(Wang, Zhu et al. 1994) and it was suggested to be involved in the regulation of 
production of NO in lymphocytes. (Costa, Auger et al. 1995) In the lacrimal gland, 
increase in NO production was proposed to play a role in lacrimal cell death in 
Sjögren‟s syndrome. (Beauregard, Brandt et al. 2003) Possible analogies could therefore 
be implied, but the functional significance of the M5 receptor in Sjögren‟s syndrome 
needs to be defined in further experiments. 
     The outcomes of this thesis show that the muscarinic receptor expression in the 
lacrimal gland should be investigated further, as it seems that the M3 receptor is not the 
sole muscarinic receptor in the lacrimal gland. The function of the other subtypes needs 
to be determined. Following experiments investigating the changes in muscarinic 
expression during inflammation should also be carried out, as these as the changes in 
the muscarinic network may be relevant in Sjögren‟s syndrome, as well as other dry eye 
diseases.  
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7 Conclusions 
 
 
The present study shows: 
 
 
1) The M3 receptor is probably not the exclusive muscarinic receptor subtype in 
the lacrimal gland, M1 and M5 receptors may also be present. The M5 receptor 
may even be localized intracellularly, possibly on the nuclear membrane.            
2) No conclusions could be drawn about the changes in the muscarinic receptor 
expression in the lacrimal and submandibular glands under normal and 
inflammatory conditions.  
3) Our model of inducing inflammation is probably not effective enough to induce 
changes in muscarinic receptor expression, or chronic inflammatory 
circumstances are necessary.  
4) In human labial glands with autoimmune focal sialadenitis compatible with 
Sjögren‟s syndrome, the following changes in the expression of muscarinic 
receptors were detected: slight down-regulation of the M1 subtype, up-
regulation of the M3 and M5 subtype.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 67 
8 Appendix 
 
8.1 Protocol to immunohistochemistry – Immunoenzyme 
ABC method 
 
 
Day 1 
 
1) Incubate the sections at 60 ºC for 60 minutes. 
2) Deparafination: 
 2 x 30 minutes in xylene 
   2 x 5 minutes in 99,5 % ethanol 
   2 x 5 minutes in 95 % ethanol 
   5 minutes in 85 % ethanol 
   5 minutes in 70 % ethanol 
3) Rinse in running water for 10 minutes. 
4) Wash in TBS 2 x 5 minutes. Prepare 1 l of citrate buffer. 
5) Rinse in citrate buffer for 5 minutes. Cook in citrate buffer for 6 minutes and 
then 3 x 5 minutes at max effect in microwave oven. Refill the evaporated citrate 
buffer to 0.2 l in each round to avid the section from cooking dry.  
6) Cool for 30 minutes in citrate buffer. 
7) Wash in TBS 2 x 5 minutes. 
8) Mark the area around the section using a hydrophobic pen. The marking should 
stay in place during the whole experiment; if leakage occurs, it has to be 
improved. 
9) Block non-specific protein binding with 5% goat serum in TBS for 30 min. 
(Depending on the size of the section the need may vary from 25 to 100 l per 
section) 
10)  Incubate with primary antibody 100x diluted in 1 % goat serum in TBS 
overnight. The box for placing the sections in during the incubation should be 
closed, sealed by tape and filled with 200 ml of water to prevent the sections 
from drying. The negative controls are incubated with only 1% goat serum in 
TBS. 
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Day 2 
 
1) Wash in TBS 2 x 5 minutes. 
2) Incubate with anti-rabbit secondary antibody of the ABC kit for 30 minutes in the 
box under the same conditions as during the night. The solution is to be prepared 
according to the manual for the Santa Cruz ABC kit. ( Mix 75 μl of normal goat 
blocking serum, 5 ml TBS and 25 μl of biotinylated secondary antibody.) All the 
solutions of the ABC kit should be prepared fresh, especially the peroxidase 
substrate.  
3) Wash in TBS 2 x 5 minutes. 
4) Prepare the AB reagent of the ABC kit ( Mix 50 μl of reagent A-avidin, 50 μl of 
reagent B-biotin and 2.5 ml of TBS). 
5) Incubate with the AB enzyme reagent for 30 minutes. 
6) Wash in TBS 2 x 5 min. 
7) Prepare the peroxidase substrate of the ABC kit (mix 1,6 ml of MiliQ water, 5 drops 
of substrate buffer, 1 drop of DAB chromogen and one drop of peroxidase 
substrate). 
8) Incubate with peroxidase substrate until the section turn brown (usually 5-6 
minutes).  
9) Rinse carefully in running deionised water for 10 minutes.  
10) Stain with haematoxyline for 5-6 minutes until the sections get intense red/purple 
colour. 
11) Rince in 37°C running water until the sections turn blue.  
12) Immerse the slides into ethanol increasing concentrations of ethanol and two times 
xylene, 10 minutes per bath.  
13) When almost dry, put a small drop of Pertex on the top of each section and cover 
with a coverslip.  
 
Solutions  
 
Citrate buffer: 
A: 0,1 M citric acid: 21,01 g C6H8O7xH2O in 1000 ml distilled H2O (dH2O) 
B: 0,1 M sodium citrate: 29,41 g Na3C6H5O7x2H2O in 1000 ml dH2O. 
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At use, mix 18 ml A, 82 ml B and 900 ml dH2O. 
TBS: 
A: 10xNaCl: 85 g NaCl (Sigma) in1000 ml dH2O. 
B: 10xTrizma base: 60,57 g Trizma base (tris (hydroxymethyl) aminomethan) in 1000 
ml dH2O. 
At use, mix 100 ml A, 100 ml B and 800 ml dH2O. 
 
8.2 Protocol to immunohistochemistry – Immunofluorescent 
method 
 
 
Day 1 
   
The protocol for the first day is the same as for the previous method. 
 
Day 2 
1) Wash the sections 2 x 5 min in TBS.  
2) Incubate, in a closed box, with fluorescent secondary antibody (1:250) in TBS 
containing 1 % of BSA for 1 hour (Light sensitive) 
3) Wash the sections 2 x 5 min in TBS. Work in darkness or shadow. 
4) Immerse the section for 10minutes in each bath:  
70 % ethanol 
85 % ethanol 
(2 x) 95 % ethanol 
(2 x) 99,5 % ethanol 
Work in darkness or shadow. 
5) Let the sections dry in darkness. Mount with ProLong medium, just a small drop 
for each section and put the cover glass on it. Sections are to be stored in 
darkness. 
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9 Abbreviations 
 
 
ABC – avidin-biotin complex 
ADP – adenosine-5„-diphosphate 
ANS – autonomic nervous system 
ATP – adenosine-5„-triphosphate 
BSA – bovine serum albumin 
cAMP – cyclic adenosine-5„-monophosphate 
CGRP – calcitonine gene-related peptide 
CRP – C-reactive protein 
DAB – 3-3„-diaminobenzidine 
DAG – diacylglycerol 
4-DAMP – 4-diphenyl-acetoxy-N-methyl-piperidine 
EDTA – ethylenediaminetetraacetic acid 
EGF – epidermal growth factor 
GDP – guanosine-5„-diphosphate 
GTP – guanosine-5„-triphosphate 
IgE – immunoglobulin E 
IHC – immunohistochemistry 
1,4,5-IP3 – 1,4,5-inositol triphosphate 
IL – interleukin 
LPS – lipopolysaccharide 
mAchR – muscarinic acetylcholine receptor 
MAPK – mitogen-activated protein kinase 
NANC – non-adrenergic, non-cholinergic 
NO – nitric oxide 
PDGF – platelet-derived growth factor 
PIP2 – phosphatidylinositol-bisphosphate 
PLC – phospholipase C 
PLD – phospholipase D 
PKC – protein kinase C 
TNF – tumour necrosis factor 
VIP – vasoactive intestinal peptide 
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